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Chronic Kidney Disease is a leading cause of morbidity, impaired quality of life and premature 
death in patients with Fabry disease, being of major public health significance. 
Glycosphingolipids that accumulate in Fabry disease due to alpha-galactosidase A (α-gal A) 
deficiency in the lysosomes localize to membrane microdomains, which play crucial roles in 
protein clustering, membrane trafficking, and especially cell signaling. The mechanisms by 
which increased levels of these glycosphingolipids and consequent changes in microdomain 
dynamics and lysosomal dysfunction all result in cellular and organ injury are not well 
understood. To effectively study Fabry disease disease mechanisms at the cellular level, I first 
established and characterized an epithelial kidney cell model of Fabry disease in Madin-Darby 
canine kidney (MDCK) cells using small interfering RNA (siRNA). I then examined plasma 
membrane protein dynamics of a model raft-associated protein, GFP-GPI, in this model system. 
Number and Brightness Analysis in live cells showed a significant increase in the oligomeric size 
of antibody-induced clusters in α-gal A silenced cells compared to control cells. To explore 
possible consequences of these findings in signaling pathways that are relevant to human disease, 
I generated human kidney cell models of Fabry disease in immortalized podocytes and tubule 
epithelial cells (HK-2) applying the genome editing technique of Clustered, Regularly 
Interspaced, Short Palindromic Repeats and associated endonuclease 9 from S. pyogenes 
SIGNALING PATHWAYS IN CELL MODELS OF FABRY DISEASE 
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Anatália Labilloy, Ph.D 
University of Pittsburgh, 2015
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(CRISPR/Cas9). I compared the abundance and phosphorylation of relevant signaling proteins in 
Fabry disease and control immortalized human podocytes using a high-throughput 
phosphorylation microarray. Fabry disease podocytes showed significant changes in total protein 
abundance and/or phosphorylation in 59 proteins. Pathway analysis predicted differential 
signaling of several canonical pathways in Fabry disease podocytes. These studies provided for 
the first time an understanding of raft protein dynamics and signaling in kidney cells deficient for 
α-gal A, potentially opening new avenues for biomarker discovery and drug development for 
Fabry disease nephropathy. 
Keywords: Fabry disease, glycosphingolipids, lipid rafts, alpha-galactosidase A, signaling, 
nephropathy 
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1.0  INTRODUCTION 
1.1 PUBLIC HEALTH SIGNIFICANCE 
Chronic kidney disease (CKD), defined as decreased glomerular filtration rate and/or significant 
loss of albumin in the urine, represents a heterogeneous group of conditions with overlapping 
clinical features and usually poor health outcomes [1]. CKD has a rising prevalence, affecting 
over 26 million individuals in the US alone, with an annual cost of over 17 billions USD per 
year, which encompasses almost one quarter of the total Medicare budget [2].  
Due to the public health impact of CKD, Healthy People 2020 (HP2020), a national 
public health program set by the United States Department of Health and Human Services to 
improve the health of all individuals in the US, includes as one of its goals to “reduce new cases 
of CKD and its complications, disability, death and economic costs” [3]. 
The majority of males and a significant proportion of female patients with Fabry disease, 
an X-linked inherited disorder, develop progressive loss of kidney function, which represents a 
major cause of decreased quality of life and premature death in these patients [4, 5]. In addition 
to CKD, other life-threatening clinical manifestations of Fabry disease such as stroke and heart 
failure also contribute to significant burden, with public health implications. 
Diagnosis for Fabry disease has been recently incorporated into national newborn 
screening programs of several countries and is being performed as pilot studies in several states 
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of the USA [6-10]. Newborn screening programs have been one of the most successful public 
health initiatives to improve health outcomes and to prevent significant morbidity and early 
mortality of individuals through early diagnosis and intervention of serious conditions [11]. 
The only clinically available therapy for Fabry disease at the moment in the US is 
enzyme replacement therapy (ERT) by intravenous administration of agalsidase beta, which has 
an estimated yearly cost of over 210,000 USD per patient [12]. Unfortunately, ERT has not 
shown to be effective in preventing loss of kidney function in Fabry disease patients, especially 
for those who start therapy at later stages of CKD [13]. 
A better comprehension of the pathophysiology of Mendelian genetic conditions such as 
Fabry disease, as well as complex disorders that share some of the disease mechanisms, can 
foster biomarker discovery and drug development, which can potentially improve quality and 
effectiveness of care provided to these patients. Translational research, in this sense, allows for 
“research [ing] for new insights and innovative solutions to health problems”, which is 
considered one of the 10 Essential Public Health Services according to the National Public 
Health Performance Standards (NPHPS) of the Centers of Disease Control and Prevention 
(CDC) [14]. 
1.2 FABRY DISEASE 
Fabry disease is a X-linked progressive multisystem lysosomal storage disease (LSD) caused by 
absence or dysfunction of the hydrolase alpha-galactosidase A (α-gal A), encoded by the gene 
GLA. Intra-lysosomal deficiency of α-gal A leads to progressive buildup of its substrates, 
mainly globotriaosylceramide (Gb3), in a variety of cell types and tissues, leading to organ 
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dysfunction with increased morbidity and early death. Fabry disease occurs in individuals of 
both genders, and classically presents with renal, cardiovascular, neurological, 
gastroenterological, ocular, auditory and dermatological findings, among others [15]. 
Drs. William Anderson (England) [16] and Johann Fabry (Germany) [17] independently 
described from a clinical perspective the first patients with the condition in 1898. The following 
timeline provides a historical perspective of major contributions to the understanding of disease 
pathogenesis and advancements in development of disease-specific therapy in Fabry disease.   
 
Figure 1. Timeline of Fabry disease. 
 
Fabry disease is pan-ethnic and fairly under-diagnosed, with unknown prevalence in the 
general population. Several population-wide screenings in specific countries yielded prevalence 
from 1:476,000 in Australia [18] to 1:77,500 in the Czech Republic [19]. Targeted screening 
focusing on specific high-risk patient subpopulations such as adult patients with unknown cause 
of renal failure [20-24], stroke [25] or hypertrophic cardiomyopathy [26] have been successful 
in identifying individuals with the condition.  
More recently, newborn screening initiatives have attempted to better estimate the 
incidence of the disease, which showed a varied but much greater than expected incidence, such 
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as 1:2,913 in the state of Missouri [9], 1:7,057 in Japan [6] 1:1,250 in Taiwan [7] and 1:3,100 in 
Italy [8]. These newborn screenings for the condition revealed a greater than expected number 
of patients predicted to have variants of the disease predicted to present later in life, raising 
some ethical concerns regarding neonatal diagnosis of adult-onset diseases. 
1.2.1 Alpha-galactosidase A 
Alpha-galactosidase A (EC 3.2.1.22), also known as melibiase or alpha-D-galactosidase 
galactohydrolase, is a homodimeric glycoprotein that hydrolyzes Gb3 into lactosylceramide as 
well as catalyzes melibiose into galactose and glucose. Other substrates for α-gal A include 
glycolipids, glycoproteins, and oligosaccharides, including the blood antigens B, B1, Pk and P1. 
Upon substrate binding, the lysosomal hydrolase cleaves terminal alpha-galactosyl residues 
producing a free α-anomeric galactose through two successive hits on the same carbon and 
requires Mg2+ and NAD+ as co-factors [27]. The biochemical properties of α-gal A of Fabry 
disease patients differ from those of healthy individuals, with significantly lower Km and Vmax 
for mutant α-gal A compared to the wild type enzyme [28]. 
  The crystal structure of the α-gal A can be seen in Figure 2. The protein has a length of 
429 amino acids, with nucleophile and proton donor active site located at residues 170 and 231, 
respectively, and substrate binding at residues 203 to 207. The enzyme belongs to the glycosyl 
hydrolase 27 family (GH27) and is synthesized in the endoplasmic reticulum as a precursor 50.5 
KDa glycoprotein, processed into a mature 46 KDa form and post-translationally modified in 
the Golgi for by addition of mannose-6-phosphate (M6P) and three N-linked glycans (N139, 
N192 and N215) [29, 30]. The enzyme is then targeted to the pre-lysosomal/endosomal 
compartments through interaction with mannose-6-phosphate receptors,. A portion of the 
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synthesized α-gal A is secreted through exocytosis, and can then re-enter the cells through 
surface M6P receptors and be delivered to the lysosomes.  
 
 
Figure 2: The crystal structure of α-gal A. 
Panel a represents the monomeric form of α-gal A, with N-terminus in blue and C terminus in red. 
Domain 1 contains the active site. Panels b and c show the dimeric form of α-gal A, and panel d shows 
two views of the molecular surface.  
Reproduced with permission from [27]. 
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Alpha-galactosidase A has an isozyme, alpha-galactosidase B, which presents similar 
physicochemical features but different charges and substrate affinities. Alpha-galactosidase B is 
an α-N-acetylgalactosaminidase and is the biochemical defect of Schindler and Kanzaki 
diseases. [31, 32] 
1.2.2 Globotriaosylceramide  
Gb3, also termed ceramide trihexoside (CTH), galactosyl-α1-4-galactosyl-β1-4-
glucosylceramide, P’ antigen or CD77, is a glycosphingolipid synthesized from 
lactosylceramide through action of the enzyme α-1,4-galactosyltransferase Gb3 synthase in the 
Golgi apparatus. This enzyme is ubiquitously expressed in humans, with highest expression in 
the kidney and the heart. [33] After its synthesis in the Golgi, Gb3 reaches the outer leaflet of 
the plasma membrane via vesicle-mediated transport, being incorporated mainly in lipid rafts 
[34, 35]. Besides bound to membranes, Gb3 can also be found associated to LDL in the plasma. 
[36] 
Increases in Gb3 are not specific for Fabry disease and are observed in other inherited 
conditions, such as in Zelglweger syndrome, a peroxisome biogenesis disorder, [37] and in 
individuals with a Pk blood phenotype [38]. Gb3 also accumulates in acquired conditions such 
as Burkitt lymphoma and in patients with other solid tumors such as breast cancer [39]. The 
apolipoprotein E knockout mice also presents elevated levels of Gb3 [40].  
In addition, increases in Gb3 are seen as a physiological response to lipopolysaccharide 
exposure during the acute phase response in the liver [41, 42]. Gb3 has been implicated in 
gp120 binding during HIV-1 infection in lymphocytes [43] and is the preferred receptor for 
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Shiga toxin 1, verotoxin 1 [44] and for uropathogenic E. coli R45 binding [45]. Gb3 also 
anchors the molecular chaperone Hsp70 to the plasma membrane, facilitating its role in 
translocation of unfolded proteins across membranes [46, 47]. Desselle et al [48] have 
demonstrated that the use of monoclonal antibody against Gb3 inhibits endothelial cell 
proliferation, angiogenesis and tumor growth and invasiveness.  
A growing body of evidence shows that globotryaosylsphingosine, the deacylated form 
of Gb3 (lyso-Gb3), may play an important role in the pathogenesis of Fabry disease. [49, 50] 
Lyso-Gb3 presents an inhibitory effect over native and recombinant α-gal A, as it tightly 
associates with the enzyme but it is degraded at a rate 50 times slower than for Gb3. [51] 
Clinically, patients with higher lyso-Gb3 levels are more likely to present classic disease 
phenotype and its levels could potentially be a more reliable biomarker of poor outcome to 
Enzyme replacement therapy (ERT). [52, 53] In addition, in vitro studies demonstrated that 
lyso-Gb3 sensitizes peripheral nociceptive neurons by enhancing voltage-dependent Ca2+ 
currents. [54] In podocytes, lyso-Gb3 increases expression of TGF-β1 and of CD74 [55]. 
1.2.3 Genetics 
Alpha-galactosidase A is encoded by GLA, a 12 kb gene mapped to Xq22.1, composed of seven 
exons ranging in length from 92 to 291 nucleotides. The first exon contains a 60 nucleotide 5’-
UTR and the nucleotide sequence for a signal peptide of 31 residues [56]. Nucleotides encoding 
for the substrate-binding motif are present in exon 3. The 5’ flanking region also contains 
several regulatory elements such as TATA-like sequences, CCAAT box sequences and the GC 
box consensus sequence for the zinc finger transcription factor Sp1. The gene also contains 
recognition motifs for enhancer binding sites such as AP1, OCTA and c-fos and lacks a 3’ 
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untranslated sequence. [56] Interestingly, some polymorphisms in GLA 5’UTR affect GLA 
expression in a cell-type specific manner, which might have implications in the phenotypic 
variability seen in these patients. [57]  
GLA mutations that cause Fabry disease affect synthesis, processing, stability, 
lysosomal targeting or substrate binding or activity of α-gal A, resulting in enzyme deficiency at 
the lysosome. [58] To date, a total of 632 different mutations have been publicly described for 
Fabry disease, the majority of them being missense. Table 1 shows a frequency distribution of 
these mutations according to HGMD. [59] 
Table 1: Types and frequencies of GLA gene mutations. 
Adapted from HGMD [59]. 
 
As most mutations are private, genotype-phenotype correlations are difficult to estimate; 
however, pathogenic mutations predicted to cause complete loss of function of the protein are 
expected to cause more severe disease phenotype. [60] 
Mutation type Number of mutations 
Missense 431 
Small deletions 94 
Splicing 34 
Small insertions 32 
Gross deletions 22 
Small indels 9 
Complex rearrangements 6 
Gross insertions/duplications 2 
Regulatory 1 
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1.2.4 Clinical Phenotype and Natural History 
Fabry disease is a highly heterogeneous condition, with a usual progressive appearance of signs 
and symptoms in childhood and early adulthood. Early reports classify Fabry disease as an X-
linked recessive condition, in which females are asymptomatic carriers. However, observations 
of several clinicians that female relatives also presented symptoms compatible with the disease 
led to a more thorough investigation of this population. Natural history studies have then shown 
that females may present full spectrum of the disease, although usually with a delayed 
presentation when compared to their male counterparts. [61, 62] Skewed X-chromosome 
inactivation has been proposed as the main mechanism for the observation of symptomatic 
females in Fabry disease. [63] While the precise mechanism for possible skewed X-
chromosome inactivation in Fabry disease remains unknown, several factors in general can lead 
to skewed X-chromosome inactivation such as imprinted X inactivation, stochastic events or a 
positive selection with survival or proliferation advantage for the mutated X-chromosome 
during early development. [63, 64] 
Patients with classic disease phenotype present signs and symptoms of the disease in the 
first decade of life, with a mean age of onset of 6 years for boys and 9 years for girls. 
Commonly, the disease first manifests as chronic or episodic neuropathic pain, triggered or 
exacerbated by changes in temperature, stress or physical exercise as well as non-specific 
recurrent gastrointestinal symptoms such as abdominal pain or distension, nausea and changes 
in bowel habits [65]. Other signs and symptoms that are common in childhood include fatigue, 
dyshidrosis and angiokeratomas. 
Chronic kidney disease is an important cause of increased morbidity and mortality in 
Fabry disease. The majority of male patients present significant decline in kidney function 
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overtime, which is also seen in 39% of females. [5] Albuminuria and overt proteinuria can be 
seen in children and adolescent of both genders, which can culminate in end-stage renal disease 
with need for renal replacement therapy. In kidney pathology, glomerulosclerosis and interstitial 
fibrosis may be present early in life and even before clinical kidney disease can be detected, 
along with signs of podocyte injury such as segmental effacement of foot-processes [66, 67]. 
Fabry registry data points to a life expectancy of 58.2 years for males and 75.4 years for 
females with FD, compared to 76 and 80.9, respectively, in the US general population [68]. 
Cardiovascular disease is the most common cause of death among Fabry disease patients [68]. 
Other major cardiac events such as myocardial infarction and heart failure can also occur in the 
4th or 5th decade of life [69]. Other cardiac findings include concentric left ventricular 
hypertrophy with early diastolic dysfunction, which may progress to systolic dysfunction and 
left ventricular outflow obstruction, arrhythmias and valvulopathies. Progressive heart fibrosis 
is seen, being first detected in the mid-myocardial layers and potentially evolving to transmural 
fibrosis with disease progression [70, 71]. 
Cerebrovascular involvement is also a major cause of death among Fabry disease 
patients, most commonly manifested by transient ischemic attacks and stroke. Other 
manifestations include dizziness and headaches. Progressive pathological changes to the micro- 
and macrovasculature, with thickening of the media and arterial remodeling are seen in both 
males and females [72]. The most commonly observed sign of CNS disease seen in MRI is the 
presence of white matter lesions, which progress with age and are thought to be caused by a 
combination of microvascular and neuronal involvements. Vertebrobasilar dolichoectasia and 
higher signal intensity of the pulvinar thalamic nuclei (i.e. the pulvinar sign) can also be seen 
[73]. 
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Currently, three disease severity scoring systems have been validated for FD patients: 
MSSI (and its modified FOS-MSSI) [74, 75], DS3 [76] and FIPI [77], the latter also conferring 
some prognostic value. The phenotypic variability seen in this patient population hinders 
disease course prediction. Lukas et al. [78] proposed a comprehensive molecular analysis for 
phenotype prediction. This algorithm combines functional characterization of GLA mutations, 
lyso-Gb3 measurements, and α-gal A biochemical and crystallographic analysis as well as 
responsiveness to the pharmacological chaperone 1-deoxygalactonojirimycin (DGJ), being able 
to predict classic/severe vs. mild disease.  
1.2.5 Diagnosis 
Fabry disease is under-diagnosed and often misdiagnosed, especially due to the absence of a 
pathognomonic finding and the multitude of clinical findings that often overlap with other 
conditions [79]. 
Diagnostic testing upon clinical suspicion can be performed by either measurement of α-
gal A enzyme activity and/or molecular testing. For males, demonstration of low α-gal A 
enzyme activity in leukocytes or cultured fibroblasts (less than 5 percent of mean reference 
value) is sufficient for the diagnosis, and sequence analysis of GLA gene can be confirmatory. 
Female Fabry disease patients can have normal enzyme activity levels, thus sequence analysis 
of the GLA gene is considered the test of choice for this population [80]. Nevertheless, 
Pasqualim et al. recently proposed a novel approach for screening females with positive family 
history and strong clinical suspicion using α-gal A enzyme activity in plasma and leukocytes at 
a different cutoff than of males [81].  
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Deletion/duplication analysis can be performed in patients that lack PCR amplification 
of a certain exon and for patients with strong clinical suspicion and negative sequence analysis 
[82]. 
For patients with an uncertain diagnosis, such as the presence of a variant of uncertain 
significant in the GLA gene, biopsy of a target organ (i.e. kidney, heart) demonstrating of ultra-
structural changes compatible with the disease in the absence of drugs that induce lysosomal 
lipidosis is diagnostic [83, 84].  
For male patients, α-gal A enzyme activity in leukocytes often correlates with 
phenotype, as patients with non-detectable enzyme activity usually present with classic or 
severe disease phenotype whereas patients with residual activity may develop later-onset 
disease [85]. 
Fabry disease should be considered as a differential diagnosis of conditions such as 
multiple sclerosis [86], cryptogenic transient ischemic attack or stroke [87], sensory peripheral 
neuropathies or neuropathic pain [88, 89], some auto-immune conditions such as rheumatoid 
arthritis and systemic lupus erythematous [90], Crohn’s disease [91], familial lymphedema [92], 
familial Mediterranean fever [93] and in patients with vortex keratopathy associated with 
conjunctival and retinal vascular tortuosity [94] among others.  
1.2.6 Management 
Several consensuses and clinical practice guidelines have been published in the past decade for 
both diagnosis and clinical management of Fabry disease for different countries [95-99]. Two 
enzyme replacement therapy (ERT) options are currently available in most countries: agalsidase 
alfa (Replagal®, Shire) and agalsidase beta (Fabrazyme®, Genzyme). In the United States, 
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agalsidase beta is the only FDA approved drug available clinically and other treatment options 
are currently under investigation. 
Long-term longitudinal studies show a variable clinical response to ERT. In addition, 
ERT does not completely prevent the occurrence of severe clinical events, such as stroke, end-
stage renal disease and sudden death [100]. Decline in renal function usually persists despite 
long term ERT, just at a slightly decreased rate. However, GFR decline is slower for patients 
with low renal involvement at baseline than for patients that have greater renal involvement 
when they start ERT [13]. For patients without proteinuria at baseline, long-term ERT might be 
associated with a slight increase in eGFR.  
Other commonly used symptomatic therapies include: angiotensin receptor 
blockers/angiotensin converting enzyme inhibitors for proteinuria; gabapentin, carbamazepine 
or diphenylhydantoin for acroparesthesias as well as anti-arrhythmic, beta-blockers and calcium 
channel blockers for hypertrophophic cardiomyopathy.  
1.2.7 Disease models 
The first animal model of the disease was generated by Ohshima et al. [101] The Gla knockout 
(KO) mice show complete absence of α-gal A and histopathological evidence of Gb3 
accumulation, however these Gla KO mice fail to reproduce classic phenotype of Fabry disease, 
especially the nephropathy, a major clinical manifestation of the disease [102]. A transgenic 
mouse model expressing a human mutant α-gal A with an R301Q substitution, thought to cause 
a “cardiac variant” of the disease, was also generated. However, these mice also appeared to be 
healthy [103], even when crossbred with the Gla KO mice, but are used for testing biochemical 
efficacy of chaperone therapy in vivo [104].  
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More recently, another Fabry disease mouse model has been generated by crossbreeding 
Gla KO mice with transgenic mice that express Gb3 synthase [105]. These mice show a greater 
accumulation of Gb3 when compared with the Gla KO mice. More importantly, these mice 
show signs of glomerular and tubular proteinuria and progressive increase in BUN with age, 
indicating impaired kidney function. However, these mice still fail to fully reproduce all aspects 
of Fabry nephropathy seen in patients, as they show no histological signs of glomerulosclerosis 
or podocyte foot process effacement [105]. 
Several cell models have also been generated for Fabry disease. Inagaki et al. described 
the first attempt of a cell model of Fabry disease using SV40 immortalized umbilical venous 
human endothelial cells. Treatment with chloroquine induced 70-80 percent reduction in α-gal 
A enzyme activity, with only 5 percent reduction in β-glucosidase, β-hexosaminidase and β-
glucuronidase [106]. Shu et al. isolated and characterized primary cultures of aortic endothelial 
cells from wild-type and Gla KO mice [107]. In a like manner, Shen et al. established a more 
physiologically relevant microvascular endothelial cell model from skin biopsy specimens 
obtained from Fabry disease patients and healthy controls [108]. Recently, cardiomyocytes were 
derived from induced pluripotent stem cells (iPSC) from Fabry disease patients [109]. Kawagoe 
et al. had also generated iPSC from Fabry disease patients, but these cells failed to differentiate 
into neuronal cells or cardiomyocytes [110].  
For the purpose of modeling the renal disease in vitro, Thomaidis et al. generated the 
first kidney cell models of the disease in HK-2 and human primary tubular epithelial cells using 
transient and stable RNA interference approaches. They reported accumulation of Gb3/CD77 
and ultrastructural changes compatible with Fabry disease, and observed a decreased viability in 
these human renal epithelial cells silenced for α-gal A [111]. Using a similar approach of stable 
 15 
shRNA α-gal A silencing, Liebau et al. first generated a human podocyte cell model of Fabry 
disease [112]. However, at best, this approach was able to reduce mRNA levels of α-gal A by 
73%. Notwithstanding, these cells showed some degree of Gb3 accumulation by thin layer 
chromatography and in changes in the phosphorylation pattern of AKT and mTOR [112].  
1.3 LYSOSOMES 
Lysosomes are heterogeneous membrane-bound organelles that are ubiquitous in all eukaryotic 
cells, and play a critical role in the degradation and recycling of intra- and extracellular material. 
They were first incidentally discovered by De Duve in 1955, in an attempt to clarify the action 
of insulin on the liver and received their name from the Greek ‘digestive body’ [113] Their 
catabolic action is performed by hydrolases present in the lumen; they receive their extracellular 
or membrane-bond cargos through the endocytic pathway, and intracellular components through 
autophagy [114]. Their acidic pH of 4.5-5 is maintained by the action of the membrane complex 
vacuolar-type H+-ATPase [115].  
The human lysosome gene database (hLGDB) describes 435 proteins as belonging to the 
lysosomal system, which comprises resident proteins such as catalytic enzymes, structural 
proteins, transporters and receptors as well as proteins that temporarily associate with 
lysosomes such as members of the mechanistic target of rapamycin complex (mTORC) and of 
the major histocompatibility complex (MHC) [116] Lysosomal associated proteins 1 and 2 
(LAMP1 and LAMP2) are the most abundant membrane bound proteins found in the lysosome.  
Most newly synthesized lysosomal hydrolases leave the endoplasmic reticulum and are 
sorted from the trans Golgi network (TGN) to the lysosome under the guidance of a mannose-6-
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phosphate (M6P) tag, facilitating M6P receptor mediated, chathrin-dependent vesicular delivery 
to late endosomes. The acidic nature of this compartment induces dissociation of the hydrolases 
from the M6P receptor, where they start their catalytic function, allowing M6PR to be recycled 
back to the TGN. [117] Most lysosomal membrane proteins are highly glycosylated to protect 
against the highly acidic environment and digestion by luminal proteases. Transient lysosome 
membrane proteins may contain short motifs in their cytosolic tails that targets them to the 
lysosome. Several lysosomal proteins do not have a definite function established yet. [118, 119] 
A schematic representation of the lysosome with its main groups of components and its major 
intracellular functions can be found in Figure 3. 
 
 
Figure 3: Main lysosomal components and function. 
Reproduced with permission from [120]. 
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In the past years, lysosomes have changed from being considered a static degradation 
organelles to be seen as a dynamic compartment, which actively senses and responds to intra- 
and extracellular stimuli and involved in an intricate interconnection to major cellular functions, 
such as intracellular signaling, autophagy, phago- and exocytosis, plasma membrane repair and 
cell homeostasis [121]. 
The recent discovery of the action of members of the microphthalmia/transcription 
factor E (MiT/TFE) subfamily in coordinating transcription of lysosomal components has 
significantly expanded the knowledge on lysosomal biogenesis and function. TFEB, a basic 
Helix-Loop-Helix leucine zipper transcriptional factor and member of this subfamily, modulates 
expression of genes known to participate in lysosomal organization, biogenesis and function, 
including hydrolases, membrane proteins and members of the vacuolar H+ ATPase complex, 
vesicle-mediated transport and secretion as well as membrane lipid and ATP metabolic 
processes. TFEB interacts with the Coordinated Lysosomal Expression and Regulation 
(CLEAR) consensus sequence, a shared unique palindromic 10 bp motif GTCACGTGAC 
located within 200 bp from the transcription start site of these genes, inducing transcription. 
Physiological or pathological lysosomal accumulation of undegraded molecules activates 
TFEB-mediated expression of CLEAR network components [122]. 
Lysosomes serve as the cell’s center for sensing nutrients and maintaining energy 
homeostasis. They also accommodate to changes in the intra- and extracellular environment by 
changes in their size, number and intracellular distribution [123]. For instance, early nutrient 
starvation (first 4 h) induces lysosomal fusion into autophagosomes, increasing their size and 
decreasing their number, which are restored after 12 h of starvation [124]. Nutrient sensing 
takes place through the action of the mammalian target of rapamycin (mTOR) and associated 
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proteins, which are part of the multi-protein complexes mTORC1 and mTORC2. Under basal 
conditions of adequate nutrient availability and lysosomal function, mTOR phosphorylates 
TFEB, which causes the latter to associate to 14-3-3 proteins and be retained in the cytoplasm. 
Upon starvation-induced autophagy or lysosomal dysfunction, mTOR is inhibited, thus does not 
phosphorylate TFEB, which is then able to translocate to the nucleus and induce expression of 
genes involved in lysosomal biogenesis [125]. 
1.3.1 Other Lysosome Storage Disorders 
To date, over 50 disorders have been categorized as Lysosomal Storage Disorders (LSDs), each 
of them resulting from deficient activity of a specific enzyme or due to abnormalities in proteins 
crucial for lysosomal function. Their combined prevalence is 1:5,000 to 1:6100 births [114, 
126], with the most common lysosomal disorder being Gaucher disease, which is caused by 
deficiency of glucocerebrosidase [127].  
Some conditions of this group are more prevalent in the Ashkenazi Jewish population, 
such as Gaucher disease type I, Tay-Sachs disease, Mucolipidosis type IV and Niemann Pick 
type A, presenting a much greater carrier frequency compared to the general population. 
Currently, both the American College of Medical Genetics (ACMG) and the American College 
of Obstetricians and Gynecologists (ACOG) recommend carrier testing for those conditions in 
the Ashkenazi Jewish population [128]. 
In terms of shared disease pathogenesis among LSDs, mostly, the accumulation of a 
substrate or also lack of a final product can be responsible for the phenotype observed in 
individuals with some of these disorders, which occur for the majority of these conditions due to 
deficiency of a hydrolase or activator or defect in a lysosomal transmembrane protein or 
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transporter. Intralysosomal accumulation of undegraded material is typically confined to those 
cells, tissues and organs with a higher turnover of the substrate. Even though the main substrate 
that accumulates substantially differs among LSDs, this group of conditions usually shares 
some biochemical and clinical features [121]. A commonly shared clinical finding among these 
conditions is developmental impairment. One of the most known classifications for LSDs 
occurs as a function of their stored materials. This classification system includes: 
mucopolysaccharidoses, sphingolipidoses, oligosaccharidoses and glycoproteinoses and 
glycogenoses [129]. Sphingolipidoses, which include Fabry disease, are the most common class 
of LSDs.  Glycosphingolipid catabolism and associated sphingolipidoses are represented in 
Figure 4. 
 
Figure 4: Glycosphingolipid catabolism and corresponding sphingolipidosis. 
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Enzymes are shown in red and diseases resulting from defects on those enzymes are shown in blue. 
ASA, arylsulphatase A; GBA, β-glucocerebrosidase; GLA, α-galactosidase; GLB, β-galactosidase; 
HEXA, β-hexosaminidase A; HEXB, β-hexosaminidase B; NA, neuraminidase; SMase, acid 
sphingomyelinase. 
Reproduced with permission from [130]. 
 
 
Some cationic amphiphilic drugs with a weakly basic amine can precipitate and 
accumulate within acidic subcellular compartments, inducing lysosomal storage and 
dysfunction simulating an inherited phospholipidosis. More than 50 drugs in this category have 
been demonstrated to induce lysosomal storage in vitro and/or in vivo. They include 
antiarrhythmic medications such as amiodarone and disobutamide, antipsychotics such as 
promazine and chlorpromazine, antimalarials such as chloroquine and the antibiotic gentamicin 
[131, 132]. Drug-induced phospholipidosis can mimic Fabry disease [133, 134], and treatment 
with some of these drugs can cause lysosomal enzyme deficiency [106]. Thus, the use of 
cationic amphiphilic drugs should be avoided in patients with lysosomal storage disorders.  
1.4 LIPID RAFTS 
Lipid rafts are highly organized, diverse and dynamic microdomains of the plasma membrane 
and of biosynthetic and endocytic compartments that are enriched in cholesterol and 
sphingolipids and have a characteristic resident and transient protein composition [135]. Protein 
partitioning into lipid rafts is conferred by lipid modifications, such as 
glycosylphosphatidylinositol (GPI) lipid anchors and acylation, or by binding of N-glycans to 
raft-associated lectins [136, 137]. Proteins with affinity for these domains associate with rafts 
upon assembly in the Golgi complex and traffic in rafts to the plasma membrane.  
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Raft-associated cargoes are endocytosed from the plasma membrane in a clathrin-
independent manner through dynamin-dependent and -independent routes [138, 139]. 
Biophysical properties of GSLs allow them to modulate membrane curvature, conferring to 
these microdomains unique features for endocytosis [140]. From endosomes, lipid raft 
components can either recycle back to the plasma membrane, return to the Golgi, or traffic to 
lysosomes for degradation [141, 142]. Recycling of raft-associated proteins occurs at a lower 
rate than of proteins that traffic through a clathrin-dependent pathway, and changes in lipid 
composition of rafts induce changes in this recycling rate [143, 144]. 
Lipid rafts also serve as stable or transient platforms for signaling components to enable 
or inhibit signal transduction [145]. Some proteins localize almost exclusively to rafts, whereas 
others associate or dissociate from these domains upon ligand binding. [146] Residence time of 
some receptors with relatively weak affinity to rafts can also be increased by formation of 
oligomers induced by ligand binding [147]. Activated receptors can also recruit proteins that 
crosslink adjacent rafts, resulting in raft coalescence and clustering, or form protein complexes 
within the rafts to trigger specific downstream signaling events [148]. Recent functional 
proteomic studies have begun to elucidate the quality, temporality and compartmentalization of 
some of these dynamic events as well as the networks of interactions and cellular processes 
triggered by activation of raft-mediated signaling using a systems biology approach [149, 150]. 
Several signaling pathways are directly and indirectly modulated by events that take place in 
membrane microdomains, and their lipid composition is critical for their function.  
Changes in lipid rafts contribute to the pathogenesis of several human diseases including 
atherosclerosis [151], Alzheimer’s disease [152], and inflammatory bowel disease [153]. 
Impaired lipid trafficking and changes in raft composition have also been described for LSDs, 
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including Niemann-Pick type C [154], type I Gaucher disease [155], and Sandhoff [156] and 
Sanfilippo syndromes [157]. However, very little is known regarding raft-associated trafficking 
or signaling in Fabry disease. Similar to other LSDs, trafficking of exogenously added BODIPY 
LacCer, a raft-associated glycolipid probe, is defective in Fabry disease, as the lipid 
accumulates in lysosomes instead of either routing to the Golgi apparatus or recycling to the 
plasma membrane as in control fibroblasts [158]. Additionally, dipeptidylpeptidase IV (DPPIV) 
accumulates intracellularly in Fabry disease patient fibroblasts rather than localizing to the 
plasma membrane [159].  
1.5 PODOCYTE IN HEALTH AND DISEASE 
Podocytes, also known as glomerular visceral epithelial cells, are highly specialized post-
mitotic cells that along with endothelial cells and the glomerular basement membrane form the 
glomerular filtration barrier, which, as the name suggests, has the function of retaining essential 
macromolecules while allowing waste to be excreted into through urine. Urinary albumin 
excretion of up to 30 mg/g of creatinine [160] or of 150 mg of total protein over a 24 hour 
period [161] are considered physiological. Microalbuminuria and overt proteinuria are the first 
laboratory findings of an impaired glomerular filtration barrier. Both unique morphological and 
electric aspects as well as the crosstalk among those three components are important for proper 
glomerular function. 
Podocytes are comprised of three distinct morphological segments: cell body, major 
processes and foot processes [162]. In terms of polarization, the apical membrane domain of the 
podocyte faces the urinary space and contains anionic proteins such as podocalyxin and 
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GLEPP-1. The basal domain anchors the podocyte to the underlying glomerular basement 
membrane and houses integrins and dystroglycans as well as podocin [163]. The slit diaphragm, 
a modified adherens junction that connects intergiditating foot processes of neighboring 
podocytes, is the main component of the glomerular filtration barrier responsible for preventing 
plasma proteins from leaking into the urinary space [164]. This junctional domain houses a 
variety of resident and transient signaling proteins that connect the outer with the intracellular 
space and are crucial for podocyte function [165]. Perturbations in signaling originating at any 
of the membrane domains or actin-associated proteins can lead to glomerular dysfunction.   
Dynamic changes to the actin cytoskeleton triggered by intra- or extracellular signaling 
lead to modulation of podocyte morphology and function. Podocyte foot processes have a 
unique actin cytoskeleton distribution where actin can be found as contractile longitudinal 
bundle filaments as well as branched filaments in the subcortical region, where these filaments 
can be easily connected to and signal from proteins in the slit diaphragm [166]. Figure 5 shows 
a representation of previously reported signaling cascades between slit diaphragm proteins and 
the podocyte cytoskeleton. Regulatory mechanisms and key molecules to play a role in the 
interaction between slit diaphragm and the actin cytoskeleton is an area of active research [167-
169]. 
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Figure 5: Slit diaphragm proteins and their signaling to the podocyte cytoskeleton. 
Diaphragm proteins are seen in red and their downstream effectors with small GTPases in green and 
connecting signaling proteins in orange, and how they regulate podocyte cytoskeleton dynamics. 
 Figure reproduced with permission from [170]. 
 
Foot process effacement is a phenotypical result of podocyte injury characterized by 
retraction and flattening of the foot processes due to derangements in the podocyte actin 
cytoskeleton. Although not a strict prerequisite for its occurrence, foot process effacement and 
slit diaphragm dysfunction are both implicated in the pathogenesis of proteinuria in a variety of 
glomerular diseases [171]. 
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1.6 STUDY APPROACH AND METHODOLOGY 
The studies proposed herein were designed to elucidate and further characterize the effect of α-
Gal A and subsequent glycosphingolipid buildup on the trafficking, stability, and signaling of 
physiologically relevant proteins in kidney cells. Results of this work provide important 
information about the role of lipid raft structure and function as well as signaling in the 
maintenance of renal cell function in the pathophysiology of Fabry nephropathy. A better 
understanding of the effect of α-gal A deficiency on the localization and function of model 
proteins whose trafficking is well characterized under non-disease states can help unravel the 
pathogenesis of other renal signaling disorders. In addition, understanding the role of lipid raft 
sphingolipid composition in renal cell function may lead to new therapeutic approaches to treat 
Fabry disease nephropathy.  
Specific Aim 1: To dissect the consequences of α-gal A silencing and subsequent Gb3 
accumulation on lipid raft mediated cellular events (Chapter 2). 
Rationale: Changes in lipid composition of membrane microdomains have been implicated in 
the pathophysiology of a variety of human diseases, including other LSDs. Fabry disease 
fibroblasts show altered lactosylceramide trafficking [156] and cell models of the disease show 
increased levels of Gb3 at the plasma membrane [111]. Maalouf et al. have suggested an 
impaired trafficking of the membrane protein DPP-IV in Fabry disease patient fibroblasts [159], 
but no previous study has been performed in polarized cells. To better elucidate this 
relationship, I silenced the GLA gene in Madin-Darby Canine kidney (MDCK) tubular epithelial 
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cells using small interfering RNA against α-gal A. I performed RT-PCR and qRT-PCR to 
confirm reduction of α-gal A mRNA levels. I characterized these cells for substrate 
accumulation using indirect immunofluorescence against Gb3/CD77 and for ultra-structural 
changes compatible with Fabry disease by transmission electron microscopy. I also measured 
lysosomal size of LAMP-2 positive vesicles in both control and α-gal A silenced MDCK cells 
in confocal microscopy image stacks. ZO-I was used as a marker for tight junctions, and I also 
performed immunofluorescence staining for EEA1 and giantin, markers of early endosomes and 
the trans Golgi network respectively, to assess morphology and distribution of these 
intracellular compartments upon α-gal A silencing. Using this model, I characterized the effects 
of α-gal A deficiency in trafficking of model raft and non-raft associated model proteins. I also 
applied N&B analysis to examine clustering of a model raft-associated protein in living cells.  
1a. How is trafficking of raft-associated proteins compromised in α-gal A deficient cells? 
(Chapter 2). 
Several lipid modifications confer protein affinity for lipid rafts, including GPI-anchor addition, 
double palmitoylation, and sterol linkages [172]. Raft association of some proteins can also be 
conferred by interaction of their extracellular regions with specific raft components; for 
example, EGFR binding to GM3 ganglioside inhibits the kinase activity of the receptor and its 
auto-phosphorylation, translating to changes in signal transduction [173]. Trafficking of raft-
associated proteins is perturbed by changes in glycosphingolipid amount and organization at the 
plasma membrane [174], but little is known about polarized raft-associated trafficking in Fabry 
disease. To this end, I characterized the effects of α-gal A silencing on trafficking of model raft-
associated and raft-independent proteins in MDCK cells. I heterologously expressed the apical 
proteins HA, DPPIV and p75-GFP, and immunostained the endogenous basolateral proteins 
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Na+/K+ ATPase, E-cadherin and caveolin-1 and performed confocal microscopy to assess 
changes in the steady state distribution of these well-characterized raft dependent or 
independent proteins.  
1b. Are there changes in lipid raft structure or dynamics (including protein oligomerization) in 
the context of Gb3 accumulation? (Chapter 2).  
Clustering of GPI-anchored proteins has been demonstrated to be essential for their targeting to 
the apical surface, and disruption of raft structure impairs sorting [175, 176]. Additionally, 
clustering of proteins in and between lipid rafts modulates downstream signaling [177]. I used 
Number and Brightness (N&B) Analysis to assess clustering of lipid raft-associated proteins in 
control living cells and cells silenced for α-gal A. N&B analysis of fluorescence confocal 
images provides a quantitative assessment of the size as well as spatial and temporal 
organization of oligomeric protein complexes at the plasma membrane of living cells. In this 
technique, movement of very low levels of a fluorescent protein through a small confocal 
volume creates fluorescence fluctuations that are used to obtain the number and brightness of 
particles in the observation volume. Comparison of the particle brightness with the brightness of 
free GFP (or other relevant fluorophore) provides an estimate of the oligomeric status of the 
protein of interest. I induced low expression of the model raft-associated protein GFP-GPI and 
compared its oligomeric size at the plasma membrane of living control and in α-gal A silenced 
MDCK cells. Molecular brightness was normalized to that for cytoplasmatic EGFP (brightness 
= 1) and for a tandem GFP-GFP construct (brightness = 2) measured by N&B. I also performed 
N&B analysis upon antibody induced clustering. For that set of experiments, control MDCK 
cells and cells silenced for α-gal A expressing low levels of GFP-GPI were pre-incubated with 
anti-GFP antibody and cluster size was measured upon both conditions.  
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Specific Aim 2: To assess differences in modulation of signaling pathways in human kidney 
cells deficient for α-gal A. (Chapter 3). 
Rationale: In several disease states, changes in phosphorylation status of key proteins by action 
of upstream kinases or phosphatases result in aberrant activation or suppression of signaling. 
Strikingly, the intracellular events triggered by increased levels of glycosphingolipids as well as 
the molecular mechanisms by which this accumulation results in cellular and kidney 
dysfunction in Fabry disease remain largely unknown. To this end, I induced stable α-gal A 
deficiency in human kidney cell lines by disrupting the GLA gene at the genome level using 
CRISPR/Cas9. I characterized these cells phenotypically for α-gal A enzyme deficiency and 
substrate accumulation. I then performed a phosphorylation antibody array composed of 
hundreds of signaling proteins and looked for differences in the phosphorylation and total 
protein abundance between Fabry disease and control podocytes.  
2a. Generate a model of Fabry disease in human kidney cells (Chapter 3). 
As disease mechanisms and signaling pathways may vary from species to species, to dissect 
signaling differences in α-gal A deficiency that are relevant to human kidney disease, I have 
generated human immortalized podocyte and HK-2 cell lines edited for Fabry disease at the 
GLA gene using the genome editing technique of clustered, regularly interspaced, short 
palindromic repeats and associated endonuclease 9 from S. pyogenes (CRISPR/Cas9). 
CRISPR/Cas9 enables targeted genomic modifications from cells in culture to whole organisms. 
These programmable nucleases can generate double-strand breaks (DSBs) in targeted regions of 
the genome, which are repaired usually by the error-prone non-homologous end joining (NHEJ) 
machinery, resulting in indels and frameshifting, leading to gene disruption. [178] I used a 
surrogate reporter plasmid to enrich for cell populations that were genome edited. This plasmid 
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contains a RFP cassette, which is constitutively expressed, the target sequence in the genome 
and an out-of-frame hygromycin-GFP cassette. Plasmid modification at the target sequence 
introduces indels, shifting the frame and allowing for hygromycin-GFP expression. Cells can 
then be sorted using fluorescence-activated cell sorting (FACS) for RFP/GFP cells or 
hygromycin treatment. First, I enriched cell populations of podocytes and HK-2 cells through 
FACS and grew individual cell colonies. I then performed a T7 Endonuclease I assay to 
examine cells for genome editing. In this assay, PCR amplicons that include the region of 
interest are denatured through heat and self- or heterohybridized to generate homo- or 
heteroduplexes. Hybridization products are then treated with T7 endonuclease I enzyme, which 
recognizes and cleaves mismatched DNA or quaternary Holliday DNA junctions, generating a 
cleaved product that can be visualized through agarose gel electrophoresis. Podocytes 
underwent a second round of CRISPR/Cas9 treatment, targeting an additional region in the GLA 
gene, with enrichment using hygromycin. For characterization of these cells regarding the Fabry 
disease phenotype, I measured enzyme activity of α-gal A and of alpha-mannosidase as an 
internal control through a fluorometric assay using specific 4-MU substrate. I also examined at 
Gb3 levels by indirect immunofluorescence.  
2b. Which signaling pathways might be differentially activated in α-gal A deficiency? (Chapter 
4)  
Podocyte function and survival are tightly regulated by a variety of signaling pathways and gene 
networks; disruption of this signaling homeostasis by underlying pathological processes result 
in foot process effacement, changes in cell-matrix adhesion or apoptosis [179]. To explore 
different pathways that could have distinct patterns of activation under conditions of α-gal A 
deficiency, I performed a high-throughput protein phosphorylation profiling in control and α-gal 
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A deficient human podocytes using an antibody microarray. This array is probed with 1318 
well-characterized antibodies against both phosphorylated and non-phosphorylated forms of 
366 proteins of interest, allowing simultaneous analysis of phosphorylation pattern and total 
abundance of proteins involved in over 65 signaling pathways. I estimated the fold change in 
intensity for each epitope tested comparing Fabry disease to control podocytes and performed 
gene enrichment and clustering analyses as well as pathway analysis using DAVID 
Bioinformatics Resources.  
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1.7 SPECIFIC AIMS 
Progressive cardiovascular, cerebrovascular, and renal involvements are major causes of 
morbidity and premature death in patients with Fabry disease, a lysosomal storage disorder 
caused by deficiency of α-galactosidase A (α-gal A) that results in accumulation of the neutral 
glycosphingolipid Gb3. Recent screening studies in adult populations point to Fabry disease as 
an important and potentially treatable differential diagnosis in patients with cryptogenic 
ischemic stroke, left ventricular hypertrophy and end-stage renal disease of undetermined 
etiology. How increased levels of Gb3 result in cellular and organ dysfunction is unknown. Gb3 
localizes to lipid raft domains, which function in membrane trafficking and signal transduction. 
I hypothesized that accumulation of Gb3 in kidney and other cells results in changes in 
lipid raft organization and function, with implications for disease pathogenesis. I tested my 
hypothesis in the following aims: 
Aim 1: To dissect the consequences of Gb3 accumulation on raft-mediated trafficking in 
renal epithelial cells silenced for α-gal A. I hypothesized that the Gb3 build-up seen in Fabry 
disease disrupts trafficking of raft-associated proteins, with implications for the pathogenesis of 
the disease. I used biochemical and morphological assays to assess differences in protein 
distribution and polarized trafficking of physiologically relevant raft-associated proteins in renal 
epithelial cells silenced for α-gal A. I also evaluated changes in clustering and oligomerization 
of raft-associated proteins using Number and Brightness (N&B) analysis. These studies shed a 
light in the potential effects of lipid raft disruption related to glycosphingolipid accumulation in 
kidney cells. 
Aim 2: To assess differences in modulation of signaling pathways in renal cells deficient 
for α-gal A. Lipid rafts act as signaling platforms for GPI-anchored and acylated proteins. I 
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hypothesized that the increase in levels of Gb3 upon α-gal A deficiency induces changes in 
signal transduction. I genome edited human kidney cell lines at the GLA gene using 
CRISPR/Cas9 and assessed cells for α-gal A enzyme deficiency and Gb3 accumulation. I then 
examined differences in phosphorylation patterns of key signaling proteins in a high-throughput 
protein phosphorylation profiling assay in human immortalized podocytes edited fro Fabry 
disease. I performed gene enrichment and clustering analysis, as well as pathway analysis of 
candidate proteins. Together, these studies provided for the first time a comprehensive analysis 
of how alterations in a raft-associated lipid might perturb cell function to cause kidney disease.  
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2.0  ALTERED DYNAMICS OF A MODEL LIPID RAFT ASSOCIATED PROTEIN 
IN A KIDNEY CELL MODEL OF FABRY DISEASE  
Reprinted from Molecular Genetics and Metabolism, vol. 111 (2), Anatália Labilloy, Robert T. 
Youker, Jennifer R. Bruns, Ira Kukic, Kirill Kiselyov, Willi Halfter, David Finegold, Semiramis 
Jamil Hadad do Monte and Ora A. Weisz, Altered dynamics of a model lipid raft associated 
protein in a kidney cell model of Fabry disease, 184-92, Copyright (2014), with permission 
from Elsevier. 
2.1 ABSTRACT 
Accumulation of globotriaosylceramide (Gb3) and other neutral glycosphingolipids with 
galactosyl residues is the hallmark of Fabry disease, a lysosomal storage disorder caused by 
deficiency of the enzyme alpha-galactosidase A (α-gal A). These lipids are incorporated into the 
plasma membrane and intracellular membranes, with a preference for lipid rafts. Disruption of 
raft mediated cell processes is implicated in the pathogenesis of several human diseases, but 
little is known about the effects of the accumulation of glycosphingolipids on raft dynamics in 
the context of Fabry disease. Using siRNA technology, we have generated a polarized renal 
epithelial cell model of Fabry disease in Madin-Darby canine kidney cells. These cells present 
increased levels of Gb3 and enlarged lysosomes, and progressively accumulate zebra bodies. 
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The polarized delivery of both raft-associated and raft-independent proteins was unaffected by 
α-gal A knockdown, suggesting that accumulation of Gb3 does not disrupt biosynthetic 
trafficking pathways. To assess the effect of α -gal A silencing on lipid raft dynamics, we 
employed number and brightness (N&B) analysis to measure the oligomeric status and mobility 
of the model glycosylphosphatidylinositol (GPI)-anchored protein GFP-GPI. We observed a 
significant increase in the oligomeric size of antibody-induced clusters of GFP-GPI at the 
plasma membrane of α-gal A silenced cells compared with control cells. Our results suggest that 
the interaction of GFP-GPI with lipid rafts may be altered in the presence of accumulated Gb3. 
The implications of our results with respect to the pathogenesis of Fabry disease are discussed. 
Keywords: Fabry disease, lipid rafts, GPI-anchored proteins, number and brightness analysis, 
kidney, polarized sorting 
2.2 INTRODUCTION 
Fabry disease is a lysosomal storage disorder (LSD) caused by deficient activity of the 
lysosomal hydrolase α -galactosidase A (α-gal A) (EC 3.2.1.22), encoded by the gene GLA [79, 
180]. The presence of dysfunctional α -gal A or its absence leads to progressive accumulation of 
neutral glycosphingolipids with α -D-galactosyl residues, mainly globotriaosylceramide (Gb3), 
in a variety of cell types, and results in multi-system disease [15]. 
The kidney is one of the most affected organs in Fabry disease and end-stage renal 
disease is a significant cause of morbidity in these patients [181]. While advanced stages of 
chronic renal disease usually develop in middle adulthood in males, the first histological signs 
of kidney involvement are seen as early as in utero [182, 183]. Additionally, pediatric patients 
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may present early signs of nephropathy such as microalbuminuria, overt proteinuria, and 
hyperfiltration [184]. Histopathologic analyses of kidney biopsies of Fabry disease patients 
show Gb3 inclusions in most renal segments and cell types [185]. As Fabry nephropathy 
progresses, mesangial expansion, interstitial fibrosis, tubular atrophy, and glomerulosclerosis 
are often observed [186].  
Recombinant Enzyme Replacement Therapy (ERT) for Fabry disease has been clinically 
available since 2001 and its administration improves overall clinical status and quality of life of 
Fabry patients [187-189]. However, ERT regimens only slightly retard the progression of 
chronic kidney disease, and a steady decline in glomerular filtration rate is still observed in 
Fabry disease patients receiving long-term ERT [190-192]. While our understanding of the 
molecular mechanisms and clinical progression of the disease has exponentially increased over 
the past several years, the pathogenic link between glycosphingolipid accumulation and renal 
cellular dysfunction that culminates in kidney failure remains unclear. A better appreciation of 
how these are connected may contribute to identification of novel drug targets for optimized 
therapy for the disease. 
After its synthesis from lactosylceramide in the Golgi apparatus, Gb3 reaches the outer 
leaflet of the plasma membrane via vesicle-mediated transport [33, 34]. Like other 
glycosphingolipids, Gb3 resides preferentially in specialized membrane domains termed lipid 
rafts [35]. Lipid rafts constitute tightly packed dynamic assemblies of the plasma membrane and 
of biosynthetic and endocytic compartments that are enriched in sphingolipids and/or 
cholesterol [135]. Differential protein partitioning into these rafts can be conferred by lipid 
modifications such as glycosylphosphatidylinositol (GPI) lipid anchors, acylation, and 
palmitoylation, or by binding of N-glycans to raft-associated lectins [137, 193] Raft domains 
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orchestrate the distribution and diffusion of a variety of proteins and lipids to enable or prevent 
lipid-lipid, protein-lipid, and protein-protein interactions [194]. 
Lipid rafts play important roles in post-Golgi membrane trafficking, intra- and inter-
cellular signaling, and cell adhesion [145, 195, 196]. A primary function of these domains is to 
serve as scaffolds that enable the formation of higher order protein associations required for 
proper sorting and signal transduction. In polarized epithelial cells, a subset of newly 
synthesized proteins requires association with lipid rafts in the trans-Golgi network for efficient 
delivery to the apical plasma membrane [197]. Clustering of these raft-associated proteins into 
high molecular weight complexes is essential for their proper polarized delivery [198-200]. 
Similarly, oligomerization and higher order clustering of proteins is also important for the 
formation of signaling synapses in membrane microdomains in response to physiological 
stimuli [201].  
Perturbations in lipid raft composition or dynamics contribute to the pathogenesis of 
several human diseases including atherosclerosis [151] and Alzheimer’s disease [152]. 
Furthermore, changes in raft composition have been described for some lysosomal storage 
disorders such as Niemann-Pick type C [154], Gaucher disease type I [202], Sandhoff disease 
[156], Sanfilippo disease [157], neuronal ceroid lypofuscinosis [203], and Krabbe disease [204]. 
Whether lipid raft structure is altered in Fabry disease is not known, however recent studies 
have suggested that trafficking of the glycosphingolipid lactosylceramide and of the apical 
glycoprotein dipeptidylpeptidase IV are perturbed in fibroblasts of Fabry disease patients 
compared to control fibroblasts [158, 159].  
Changes in the lipid composition of lipid rafts may alter the stoichiometry of their 
protein components, with possible functional effects [205]. A recent advance in our ability to 
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study spatial and temporal dynamics of proteins in living cells is the establishment of 
fluorescence fluctuation technique of Number and Brightness (N&B) analysis. In this method, 
quantitation of temporal fluctuations in the emission intensity of fluorescent molecules is used 
to calculate the oligomerization of fluorescently-tagged proteins expressed at low levels [206-
209].  
Here we have established and characterized a polarized cell model of Fabry disease in 
the canine kidney cell line MDCK (for Madin-Darby canine kidney). Cells silenced for α-gal A 
had increased levels of Gb3 and developed ultrastructural changes consistent with those 
observed in histopathological analyses of Fabry disease patient samples. Accumulation of Gb3 
in intracellular compartments and at the cell surface did not alter the targeted delivery of either 
raft-associated or raft-independent proteins to the apical and basolateral membranes. To 
investigate lipid raft dynamics, we examined the effect of α-gal A depletion on the clustering of 
a model raft-associated GPI-anchored protein (GFP-GPI). N&B analysis in living cells revealed 
an increased oligomeric size of GFP-GPI at the plasma membrane of α-gal A silenced cells 
upon antibody-induced clustering compared with control cells. We speculate that accumulation 
of Gb3 in Fabry disease may lead to changes in protein-protein and protein-lipid interactions in 
lipid rafts.  
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2.3 MATERIALS AND METHODS 
2.3.1 Cell culture 
MDCK cells were cultured in MEM with 10% heat-inactivated fetal bovine serum. Growth 
media was replaced every 48 h. Cells at 70-90% confluence were detached using TrypLE select 
(Life Technologies), transfected as described below, and seeded on 0.4 μm Transwell® 
permeable supports (Corning Life Sciences) for up to six days prior to experiments.  
2.3.2 SiRNA-mediated knockdown 
An siRNA oligonucleotide targeting the following sequence 5’-GATAGATCTGCTGAAATT-
3’ was designed for transient silencing of the canine α-gal A using Dharmacon siDESIGN 
center (http://www.thermoscientificbio.com/design-center/). SiRNA against firefly luciferase 
(Dharmacon) targeting the sequence 5’-GAATATTGTTGCACGATTT-3’ was used as a 
control. MDCK cells were transfected with either α-gal A or control siRNA using 
Lipofectamine™ 2000 transfection reagent (Life Technologies) and Opti-MEM® I Reduced 
Serum Media (Life Technologies). Briefly, 260 pmol of either α-gal A or control siRNA were 
incubated with 10 μL of lipofectamine and 500 μL of Opti-MEM for 30 min at ambient 
temperature. An aliquot (125 μL) of the transfection mix and 5 x 105 subconfluent MDCK cells 
suspended in 333 μL of MEM with serum were seeded in 12-well plates or on Transwell® 
permeable supports. Growth media was replaced within 8 h of transfection and every other day. 
Experiments were typically performed after 3 to 4 days. For longer knockdown periods, siRNA 
transfections were repeated every 3-4 days.  
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2.3.3 PCR analysis of knockdown efficiency 
Isolation of total RNA was performed using the RNAqueous® kit (Ambion) according to the 
manufacturer’s recommendations. Purified total RNA underwent reverse transcription by 
incubation with Moloney murine leukemia virus reverse transcriptase (Ambion) at 42°C for 1 h. 
PCR of canine alpha-galactosidase was performed using the Phusion® High-Fidelity PCR kit 
(New England BioLabs, Inc.), with the following sense and antisense primers: 5’-
TGTGCAACGTTGACTGCCAAGAAG-3’ and 5’- TCCTGCAGGTTTACCATAGCCACA-
3’. As a control, canine β-actin was also amplified (sense and antisense primers 5’-
CTGCTGGAAGGTGGACAG-3’; and 5’-ACCTTCAACTCCATCATGAAG-3’). Reactions 
were run under the following parameters: 30 sec at 98oC, 5 cycles at [98oC for 10 sec, 72oC for 
30 sec, 65oC for 30 sec (reducing temperature by 1oC each cycle), 72oC for 30 sec], followed by 
27 cycles at [98oC for 10 sec, 56oC for 30 sec, 72oC for 30 sec], and a final cycle of 72oC for 10 
min. For real-time quantitative reverse transcription-PCR (qRT-PCR), 40 ng of RNA was 
loaded per experimental well. The following primers targeting canine mRNA products were 
used: α-gal A sense and antisense: 5’-ACCGGCTTAGAAAGGAAGACA-3’ and 5’-
TTTACCATAGCCACAGCCCA-3’; β-actin sense and antisense: 5’-
GATCAAGATCATCGCACCCC-3’ and 5’-ACAGTCCGCCTAGAAGCATT-3. Six-point 
standard curves were generated for each primer using progressive 1:2 dilutions of cDNA. 
Maxima SYBR (Thermo Scientific) was added to each experimental well containing sample and 
primers. qRT-PCR was performed on the 7300 Real Time System (Applied Biosystems). 
Reactions were run using the following parameters: 2 min at 50oC, 10 min at 95oC, and 40 
cycles at 95oC for 15 sec followed by 60oC for 1 min. All samples were run in triplicate and 
normalized to β-actin controls. 
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2.3.4 Recombinant adenoviruses and adenoviral infection 
Generation of replication-defective recombinant adenovirus encoding influenza hemagglutinin 
(HA) has been previously described [210]. Adenovirus encoding GFP-GPI was generated as 
described in [210]. Adenovirus stocks encoding dipeptidylpeptidase IV (DPPIV), and p75-GFP 
were generous gifts from A. Musch (Albert Einstein College of Medicine, New York, NY) and 
E. Rodriguez-Boulan (Weill Cornell Medical College, New York, NY), respectively. Sixteen to 
eighteen hours prior to experiments, MDCK cells grown on permeable supports were rinsed in 
Ca2+-free PBS containing 1 mM MgCl2 (PBS-Mg) and the indicated replication-defective 
adenoviruses (encoding HA, DPPIV, GFP-GPI, or p75-GFP) and the tetracycline transactivator 
(necessary for expression of some constructs) were added in PBS-Mg to the apical chamber at a 
multiplicity of infection of 25 to 75. PBS-Mg (500 μL) was added to the basolateral chamber 
and cells were incubated at 37oC with 5% CO2 for 1 h. Cells were then rinsed with PBS-Mg and 
incubated overnight in growth media.  
2.3.5 Indirect immunofluorescence and confocal microscopy 
MDCK cells cultured on permeable supports were fixed for 15 min in 4% paraformaldehyde, 
100 mM sodium cacodylate, pH 7.4 warmed to 37°C. Cells were then quenched in PBS 
containing 20 mM glycine and 75 mM NH4Cl for 5 min and permeabilized with 0.1% TritonX-
100 in quench solution for 8 min with gentle shaking. After blocking in 1% BSA and 0.1% 
saponin in PBS for 30 min at ambient temperature, cells were incubated in primary antibody for 
1 h. Rat IgM Anti-CD77 mAb (clone 38-13, Abcam), which recognizes Gb3, was used at a 
dilution of 1:20. Rabbit anti-giantin (from A Linstedt, Carnegie Mellon University, Pittsburgh, 
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PA) was diluted at 1:400. Mouse mAb to LAMP-2 (AC17; from E. Rodriguez-Boulan) was 
diluted at 1:2,000. Mouse mAb against the early endosomal antigen EEA1 (Affinity 
Bioreagents) was used at 1:200. Rat mAb against HA (clone 3F10; Roche Applied Biosystems) 
was used at 1:500. Rat anti-ZO-I (hybridoma R40.76 supernatant) was used neat. Monoclonal 
anti-DPPIV antibody was a gift from Ann Hubbard (Johns Hopkins School of Medicine, 
Baltimore, MD) and was used at 1:500. Rabbit polyclonal Ab against caveolin-1 (Cell Signaling 
Technology) was used at 1:300. Mouse mAb against Na+/K+ ATPase (Abcam) was used at 
1:400. Mouse mAb against E-cadherin (BD Biosciences) was used at 1:400. After incubation 
with primary antibodies of interest, cells were washed four times for 5 min each in PBS 
containing 0.5% BSA and 0.05% saponin and incubated in secondary antibody for 30 min. 
Alexa-Fluor (Invitrogen Molecular Probes) and Cy3 (Jackson ImmunoResearch Inc.) secondary 
antibodies were used at a dilution of 1:500 and 1:200, respectively. Primary and secondary 
antibodies were diluted in PBS containing 0.5% BSA and 0.05% saponin. Filters were washed 
four times for 5 min each and mounted using ProLong antifade gold with DAPI (Life 
Technologies). For surface staining, MDCK cells seeded on permeable supports were washed 
five times with HEPES/MES-buffered MEM, pH 7.0 (binding medium) for 3 min on ice. After 
blocking with HEPES-buffered MEM, 0.6% BSA, pH 7.4 for 15 min on ice, cells were 
incubated with rat IgM anti-CD77 mAb (diluted at 1:20) in binding medium on ice for 10 min. 
Cy3 goat anti-rat IgM secondary antibody was used at concentration of 1:200 diluted in binding 
medium on ice in anti-CD77 treated cells. Cells were washed five times with binding medium 
following incubation with both primary and secondary antibodies and then fixed and quenched 
as described above before, mounting using ProLong antifade gold with DAPI. Where stated, 
SYTOX Green Nucleic Acid Stain was used to visualize nuclei. Images were captured on an 
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Olympus Fluoview FV1000 laser-scanning confocal microscope and processed using ImageJ 
(National Institutes of Health, Bethesda, MD), Metamorph imaging system (Universal Imaging 
Corp, Brandywine, PA) and Adobe Photoshop® CS6. Statistical background subtraction of the 
images was performed using Metamorph Imaging system (Universal Imaging Corp, 
Brandywine, PA).  
2.3.6 Electron microscopy 
Monolayers of MDCK cells seeded on permeable supports were fixed in solution of 2.5% 
glutaraldehyde and 4% paraformaldehyde in PBS for 30 min and post-fixed in 1% Osmium 
tetroxide overnight. Samples were dehydrated in graded series of ethanol solutions and 
embedded in EPON according to standard procedures. Ultra-thin sections were stained with 
uranyl acetate and lead citrate and examined using a JEOL electron microscope. 
2.3.7 N&B measurements 
Cells transfected with control or α-gal A siRNA for three to seven days were transfected with 
0.2 μg of DNA plasmid encoding GFP fused to the GPI-anchor of 5' nucleotidase (GFP-GPI; 
provided by G. Ihrke; Uniformed Services University of the Health Sciences, Bethesda, MD) 
using Lipofectamine 2000 for 16-20 h. The oligomeric status of both GFP-tagged proteins in the 
absence or presence of 50 μg/mL rabbit anti-GFP antibody (Invitrogen) was determined by 
number and brightness (N&B) analysis as previously described [211]. Briefly, a set of 100 
confocal images for control or α-gal A silenced cells were acquired on a Leica TCS system 
equipped with a 63X/1.2 NA water objective with 488-nm laser line and 500-570 nm emission 
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filter. Images were collected at 200 Hz using a hybrid detector set in the photon counting mode. 
Measurements were performed at 37°C and the average molecular brightness (B) and number of 
particles (N) per pixel were calculated using the SimFCS software ([206]; Laboratory of 
Fluorescence Dynamics, University of California, Irvine). N and B are defined as: 
 
 
 (Eq. 1) 
 
 
 (Eq. 2) 
 
The variable k represents the signal intensity and σ is the variance of the signal. The molecular 
brightness of either control or α-gal A silenced cells was divided by the average brightness of 
monomeric GFP measured in the cytosol to obtain the normalized brightness. To measure 
expression levels of heterologously expressed proteins in the cells analyzed by N&B analysis, 
the average intensity of fluorescence of a solution containing 30 nM of purified EGFP 
(Biovision) as well as the average intensity of fluorescence of cells expressing GFP-GPI were 
measured under the same experimental settings and quantitated using SimFCS. Approximate 
concentration of GFP-GPI in each cell was determined by dividing the measured value of 
intensity of fluorescence for GFP-GPI in that cell divided by the intensity of fluorescence for 
the EGFP solution multiplied by 30 nM. For calculation purposes, we considered 
autofluorescence to be negligible under the experimental conditions assessed. 
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2.4 RESULTS 
2.4.1 SiRNA mediated silencing of α-gal A efficiently reduces of α-gal A mRNA in kidney 
epithelial cells 
Despite their lack of α-gal A activity, knockout α-gal A mice do not fully reproduce the human 
clinical phenotype of Fabry disease [101]. As alternative approaches, cell models have been 
useful tools for understanding disease cellular pathogenesis, for identifying biomarkers of 
disease progression, and for developing and testing novel diagnostic and therapeutic avenues 
[111, 112, 212, 213]. To generate a renal epithelial cell model of Fabry disease, we transfected 
MDCK cells with siRNA oligonucleotides targeting α-gal A or a control oligonucleotide. 
Because commercially available antibodies against human α-gal A failed to recognize the 
canine enzyme, we measured knockdown efficiency using RT-PCR. As shown in figure 6A, we 
observed a significant reduction in α-gal A mRNA in MDCK cells treated with α-gal A siRNA 
compared to control siRNA, without significant differences in β-actin mRNA levels. We could 
maintain this level of α-gal A knockdown for at least four days with a single transfection and up 
to six weeks by repeating the transfection every three to four days (data not shown). Efficient 
knockdown was further confirmed by quantitative RT-PCR, which showed an average of 88% 
reduction in α-gal A mRNA in α-gal A siRNA transfected cells (figure 61B).  
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MDCK cells were transfected with control siRNA or siRNA targeted against α-gal A. After three days or seven 
days with repeated transfection, cells were solubilized and mRNA was extracted. (A) The efficiency of knockdown 
was quantified by RT-PCR, and a representative gel is shown. The migration of DNA ladder standards is shown on 
the left. The predicted PCR product for α-gal A is 898 bp. β-actin was used as a PCR control (expected product size 
160 bp). (B) Quantitation of knockdown efficiency by qRT-PCR, performed as described in Methods. The mean 
+/- range of two independent experiments is plotted.  
2.4.2 Accumulation of Gb3 in MDCK cells silenced for α-gal A 
Gb3 is the main substrate of α-gal A and accumulates in a variety of cell types in Fabry disease 
patients [214]. To investigate the consequences of α-gal A silencing on cellular Gb3 levels, we 
compared the intensity and pattern of Gb3 staining in polarized MDCK cells three days after 
transfection with α-gal A or control siRNA. Cells were fixed and processed for indirect 
immunofluorescence using a monoclonal antibody against Gb3 (Anti-CD77). As shown in 
Figure 6: Efficient siRNA-mediated silencing of a-gal A in MDCK cells. 
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Figure 7, we observed a marked increase in anti-CD77 staining in MDCK cells transfected for 
three days with α-gal A siRNA compared with control siRNA. The majority of the staining was 
present in intracellular compartments likely to correspond to lysosomes. Increased levels of Gb3 
were also observed at the plasma membrane of non-permeabilized MDCK cells silenced for α-
gal A (Figure 7, bottom). Cell surface Gb3 is also known to be elevated in Fabry disease and 
measurement of this pool has been recently proposed as a means to monitor the response to 
ERT [111].  
(Top) Filter-grown MDCK cells transfected with control (left panel) and α-gal A siRNA (right panel) for 
seven days were processed for indirect immunofluorescence using anti-CD77 antibody to detect Gb3 
Gb3 and imaged by epifluorescence microscopy. SYTOX Green Nucleic Acid Stain was used to 
Figure 7: α -gal A siRNA silencing increases cellular levels of Gb3. 
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visualize nuclei. Scale bar: 10 µm (Bottom) Surface staining of CD77/Gb3 in non-permeabilized MDCK 
control cells (left) and α-gal A siRNA silenced cells (right). Maximum projections of five optical 
sections taken at the apical surface are shown.  Scale bar: 5 µm. 
2.4.3 Ultrastructural changes upon α-gal A silencing in MDCK cells 
Fabry disease patient fibroblasts have enlarged lysosomes that decrease in size upon disease-
targeted therapy [215]. We therefore examined whether α-gal A silencing altered lysosome size 
in MDCK cells. We performed confocal microscopy of MDCK cells transfected with control or 
α-gal A siRNA and immunostained for the lysosome marker LAMP-2. By visual inspection 
there appeared to be an increase in the size of LAMP-2 positive compartments in α-gal A 
silenced cells compared with cells treated with control siRNA (Figure 8A). To quantify this 
difference, the average area of individual LAMP-2 positive compartments in confocal image 
stacks was determined using ImageJ software. While there was variability in individual 
lysosome sizes, on average, the lysosomal area in α-gal A silenced cells was 233 % greater per 
field than that measured in control cells (Figure 8B). In contrast, the morphology of early 
endosomes and the Golgi complex were unaffected (supplementary figure 1). 
Light and electron microscopy of biopsied tissues of patients with Fabry disease reveals 
cell-type dependent ultra-structural changes that are characteristic of lipid deposition seen in 
LSDs [186]. In cell types with a greater degree of lipid deposition, the accumulation of 
intracellular inclusions formed of concentric or parallel arrays of lipid aggregates, also called 
“zebra bodies”, is evident by electron microscopy [216]. To investigate renal epithelial cell 
ultrastructure upon α-gal A silencing, we fixed MDCK cells six days after siRNA transfection 
and processed the samples for transmission electron microscopy (Figure 8C). Osmiophilic 
myelin-like structures similar to the zebra bodies observed in affected tissues of patients with 
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Fabry disease were observed in α-gal A silenced cells and absent in cells transfected with 
control siRNA. These structures increased in number after six weeks of repeated α-gal A siRNA 
transfection (Figure 8C). These results confirm that siRNA-mediated silencing of α-gal A 
MDCK cells reproduces the Gb3 deposition pattern and ultrastructural changes observed in 
Fabry disease patient cells. Therefore, this model can be used to study cellular processes that 
when perturbed could potentially contribute to the disease mechanism in α-gal A deficiency.  
(A) Indirect immunofluorescence of the late endosome/lysosome marker LAMP-2 in control (left panel) 
and α-gal A silenced (right panel) MDCK cells. SYTOX Green Nucleic Acid Stain was used to visualize 
nuclei. Scale bar: 10 µm (B) The average area of individual LAMP-2 positive compartments in control 
and α-gal A silenced cells was quantified using ImageJ. The graph shows data from 20 fields in three 
independent experiments. *t-test p<0.001. (C) Transmission electron micrographs of MDCK cells 
treated with α-gal A siRNA for six days (left and middle panels) or six weeks (right panel). 
Transversely-stacked, osmiophilic myelin-like membranes also known as “zebra bodies” (arrow heads) 
are evident within six days of transfection and are more prevalent after six weeks of repeated 
transfections. Scale bar: left: 2 μm, middle and right: 500 nm. 
Figure 8: α-gal A siRNA silencing causes accumulation of zebra bodies and increased lysosome size. 
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2.4.4 Polarized sorting of raft-associated and raft-independent proteins is unaffected by 
α-gal A silencing 
Association with lipid rafts is essential for efficient biosynthetic delivery of a subset of newly 
synthesized apically-destined proteins [217]. To test whether accumulation of Gb3 alters apical 
delivery pathways, we examined the steady state distribution of apical cargoes in α-gal A 
silenced polarized MDCK cells grown on permeable supports. As shown in Figure 9A, staining 
of the tight junction protein ZO-1 was unaffected by α-gal A knockdown. Moreover, we found 
no difference in the steady state distribution of the raft-associated protein HA (Figure 9B) or the 
raft-independent protein p75-GFP (Figure 9C) in α-gal A silenced cells. A previous study 
reported changes in the subcellular localization of DPPIV in fibroblasts cultured from Fabry 
patients [159]. However, we found no effect of α-gal A silencing on DPPIV distribution (Figure 
9D). Additionally, we observed no differences in the steady state distribution of the 
basolaterally targeted proteins E-cadherin and Na+/K+ ATPase, as well as the raft-associated 
protein caveolin-1 in MDCK cells silenced for α-gal A and in control cells (Supplementary 
Figure 2). Thus, Gb3 accumulation in α-gal A-depleted cells is apparently insufficient to alter 
apical sorting in our model system. 
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(A) Indirect immunofluorescence staining of ZO-I (tight junction marker) in control and α-gal A silenced 
MDCK cells confirms that tight junctions are intact. Control and α-gal A siRNA treated polarized 
MDCK cells were infected with replication-defective adenoviruses encoding (B) the raft-associated 
protein HA; (C) the raft-independent neurotrophin receptor p75 (tagged with GFP); or (D) the 
glycoprotein dipeptidylpeptidase IV (DPPIV). Cells were fixed, processed for immunofluorescence, and 
imaged by confocal microscopy. Images taken at the level of the apical surface and at a medial plane are 
shown for each protein, and xz reconstructions are below. Scale bar: 5 µm. 
 
 
Figure 9: Steady state distribution of raft-associated and raft-independent apical cargoes 
is not affected by α-gal A siRNA silencing. 
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2.4.5 Dynamics of a model raft-associated protein upon α-gal A silencing in MDCK cells 
Recent studies have demonstrated that the steady-state cellular distribution of lactosylceramide 
differs in fibroblasts of Fabry disease patients when compared to control fibroblasts, suggesting 
perturbed lipid raft trafficking in Fabry disease [158]. However, the effects of Gb3 
accumulation on lipid raft dynamics and any consequences to the pathogenesis of Fabry disease 
remain unknown. We postulated that α-gal A silencing and subsequent accumulation of neutral 
glycosphingolipids at the plasma membrane would impact how proteins interact with lipid rafts 
and potentially induce changes in oligomerization of raft-associated proteins. As a proof of 
principle we chose to study the oligomeric status of GFP-GPI in our MDCK model of Fabry 
disease. GPI-anchored proteins are well-characterized raft-associated proteins and serve as 
models to study cell processes that occur in lipid rafts [218]. GFP-GPI is efficiently recruited to 
lipid rafts, and alteration of raft composition is known to change the oligomeric state of GFP-
GPI, thus making it a useful probe for monitoring lipid raft microdomains [219].  
Using N&B analysis, we measured the self-assembly of GFP-GPI at the plasma 
membrane of MDCK cells transfected with α-gal A and control siRNA. In N&B analysis, a 
series of confocal images of cells expressing the fluorescent protein of interest are acquired and 
the average intensity and the variance of the fluorescence signal per pixel are measured. The 
molecular brightness is then calculated as the ratio of the signal variance to intensity (see 
schematic in Figure 10A). For example, considering samples with the same average in intensity 
of fluorescence, tetramers would have a four-fold greater brightness compared to monomers 
since the signal variance of the many dim monomers is much smaller compared to the variance 
of several bright oligomers as they move in and out of the confocal volume. In both control and 
α-gal A siRNA treated cells, the majority of the GFP-GPI fluorescence was uniformly 
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distributed at the cell surface, with some intracellular staining as has been previously reported 
[220] (Figure 10B). The expression level of GFP-GPI in our experiments ranged from 0.2 to 1.4 
µM, which is similar to the endogenous expression range observed for membrane tyrosine 
kinase receptors and associated downstream signaling molecules [221]. The brightness 
measured under these conditions corresponded to the total values across the area of interest 
because no identifiable puncta could be gated for analysis (see Supplementary Figure 3). The 
average molecular brightness for GFP-GPI at the plasma membrane was 2.21 and 2.24 for 
control and α-gal A silenced cells, respectively (Figure 10C, dashed line). These data are in 
good agreement with previous studies showing that under non-stimulated conditions GPI-
anchored proteins are highly mobile and form transient homodimers at the plasma membrane 
[222]. Upon activation or ligand binding, GPI-anchored proteins form stable homodimers and 
higher order clusters composed of GPI-anchored proteins and other raft-associated proteins 
[223, 224]. Experimentally, clustering of GPI-anchored proteins can be induced by addition of 
antibodies, and leads to activation of downstream signaling pathways [225]. Addition of anti-
GFP antibody for ten minutes caused rapid and visible coalescence of GFP-GPI into large 
patches at the cell surface (Figure 10B). Quantitation of the average brightness in these patches 
revealed an increase in clustering of GFP-GPI that was significantly greater in α-gal A silenced 
cells (5.08 ± 0.45; median ± SEM) compared to control cells (2.74 ± 0.24; median ± SEM; 
p<0.005; Figure 10C). Inclusion of brightness values across the region of interest (i.e., not 
limited to the patches) in these samples did not change the observation that α-gal A depletion 
leads to larger cluster size but would lead to an underestimation of the brightness in the patches 
(Supplementary Figure 3).  
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In order to determine if the change in oligomeric stability seen for GFP-GPI extended to 
non-raft membrane proteins, we next measured the molecular brightness of a lumenally GFP-
tagged version of endolyn (GFP-endolyn), an apically destined sialomucin that traffics in a raft 
independent matter [226]. The average molecular brightnesses for GFP-endolyn at the plasma 
membrane were 1.65 and 1.27 in control and α-gal A silenced cells, respectively (figure 5E, 
dashed lines). Similar to GFP-GPI, addition of anti-GFP antibody caused the rapid 
accumulation of clusters of protein at the cell surface (Figure 10D). In control cells the GFP-
endolyn clusters ranged in size from ~2-4 protein molecules per cluster with a median cluster 
size of 2.88. While GFP-endolyn in α-gal A silenced cells exhibited a much broader range of 
cluster sizes (~2-8 molecules, median 2.96; Figure 10E), cluster size in control and knockdown 
cells was not statistically significantly different. Together, our results suggest that there is 
greater stabilization of GFP-GPI oligomers in rafts of α-gal A silenced cells upon antibody-
induced clustering and that this effect does not extend globally to all plasma membrane 
proteins. 
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Figure 10: α-gal A silencing alters antibody induced-clustering of a lipid raft associated protein. 
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Schematic of the theory of number and brightness (N&B) analysis. Left: depiction of cell surface 
expression of GFP-GPI protein in the absence (-Ab), or presence (+Ab) of anti-GFP antibody (red). The 
magenta circle in the region of interest (roi) represents the focal volume of the microscope. The magenta 
hourglass is an expanded view of the focal volume with a representation of GFP-GPI clusters (membrane 
not shown for clarity) diffusing in the -Ab or +Ab conditions. Center: In this example, the total 
concentration in the roi before and after Ab addition is similar, giving rise to the same average 
fluorescence intensity (k). When antibody is added to induce clustering, the same average fluorescence 
intensity is now redistributed into a few oligomeric species within the focal volume, which causes a 
dramatic increase in the signal variance (σ) as the large oligomers diffuse through the focal volume. The 
ratio of variance to intensity is termed molecular brightness (brightness) and provides information on the 
oligomeric status of a protein when compared to the monomeric fluorescent probe. Right: Depiction of 
brightness map for the roi in the -Ab and +Ab conditions with cool and warm colors representing less 
and more clustering, respectively. (B) Control or α-gal A silenced (KD) cells expressing GFP-GPI in the 
absence or presence of anti-GFP antibody. Left panels: Fluorescence images showing control and or α-
gal A silenced cells before (-Ab), or 10 min after addition of anti-GFP antibody (+Ab); scale bar: 20 μm. 
Middle panels: higher magnification of the boxed region where N&B measurements were acquired; scale 
bar: 2 μm. Right panels: map of molecular brightness for the inset regions shown in the fluorescence 
images; heat map scale bar = normalized molecular brightness per pixel (e.g. 2 = 2 GFP molecules per 
cluster). (C) Scatter plot of normalized molecular brightness values for control and or α-gal A silenced 
cells (n=13 and n=15, respectively, from two experiments). The dotted line represents the average 
normalized molecular brightness (~2.2) for control and α-gal A silenced cells in the absence of antibody. 
*p < 0.005 by unpaired t-test. (D) Control or α-gal A silenced (KD) cells expressing GFP-endolyn in the 
absence or presence of anti-GFP antibody. Image layouts same as in panel B. (E) Scatter plot of 
normalized molecular brightness values for GFP-endolyn in control or α-gal A silenced cells (n=16 and 
n=14, respectively, from two experiments). The fine dotted line represents the average normalized 
molecular brightness for control and the coarse dotted line for α-gal A silenced cells in the absence of 
antibody (1.65  and  1.27, respectively). 
2.5 DISCUSSION 
The cellular phenotype of Fabry disease is not well understood. In particular, how the 
accumulation of the raft-associated lipid Gb3 might alter the dynamics and efficiency of lipid 
raft dependent processes has never been examined. As lipid raft formation and composition 
have been widely studied in MDCK cells for several years [196], we decided to generate a cell 
model to study raft-dependent processes using this well-characterized kidney tubular epithelial 
cell line. We effectively knocked down α-gal A mRNA levels by nearly 90% using an siRNA 
approach. MDCK cells silenced for α-gal A had elevated levels of Gb3, enlarged lysosomes, 
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and progressively accumulated zebra bodies, consistent with the cellular phenotype of Fabry 
disease in humans.  
In nonpolarized cells, lipid rafts are estimated to cover 30-40% of the plasma membrane, 
and are even more prevalent in the apical membrane of polarized cells [227]. Oligomerization of 
raft-associated proteins either by ligand binding or antibody crosslinking is known to increase 
their affinity for lipid rafts and their stabilization in these microdomains [228]. Additionally, 
oligomerization of raft components causes lipid rafts to coalesce and form larger domains [198]. 
Our results indicate that the alterations in lipid raft composition observed in Fabry disease 
induce changes in lipid raft dynamics that may occur upon activation/oligomerization of raft-
associated proteins. We speculate that this could impact raft-mediated signal transduction in 
Fabry disease.  
Using N&B analysis, we spatially mapped the dynamics of a GPI-anchored protein in 
our cell model of Fabry disease. This imaging approach allows us to measure the size of 
oligomeric complexes in live intact cells at physiologically relevant expression levels. 
Strikingly, we found that the average oligomeric size for the ligated GPI-anchored protein was 
~two-fold higher in α-gal A silenced cells compared to cells transfected with control siRNA. 
We observed ~2.5-7 molecules of GFP-GPI per oligomer upon antibody addition. This range is 
consistent with single molecule studies of the GPI-anchored receptor CD59 that identified 
clustering of 3-9 molecules of CD59 per oligomer upon gold-induced crosslinking and 
activation of the receptor [220]. In contrast, the clustering of a lipid raft independent protein 
was not significantly affected in α-gal A silenced cells suggesting that the observed change in 
oligomeric stability was specific to raft proteins. Measurements in live cells are critical given 
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recent studies demonstrating that remodeling of G protein coupled receptors and GPI-anchored 
protein complexes can occur on the millisecond to second timescale [229-231]. 
What are the implications of our results with respect to Fabry disease? High-resolution 
studies of CD59 have identified transient stalling, or immobilization, as a key requirement for 
the recruitment of downstream signaling effectors, such as Lyn kinase and PLCγ2, to activate 
intracellular calcium signaling [220, 232]. The increased oligomer size we observed of a model 
GPI-anchored protein upon α-gal A depletion might represent “stalled” oligomers due to 
alteration in lipid-lipid interactions or protein-lipid interactions. Thus, we predict that signaling 
from raft-associated complexes may be altered in Fabry disease. In this regard, one signaling 
pathway that will require future exploration in the context of α-gal A silencing is that mediated 
by TGF-β. TGF-β signals through three different receptor isoforms that traffic via both raft-
dependent and raft-independent pathways [233]. The binding ratio of monomeric TGF-β to 
heterotetrameric complexes of these receptors differs upon membrane compartmentalization, 
resulting in activation of different downstream effectors [234]. Human podocytes loaded with 
lyso-Gb3, the deacylated form of Gb3, showed increased expression of TGF-β1, which 
mediates an increase in the expression of the extracellular matrix components fibronectin and 
collagen type IV [235]. This dysregulation of TGF-β signaling was proposed as a contributor to 
development of glomerular injury in Fabry disease. The cell model that we have developed 
combined with N&B analysis will be a powerful tool to dissect the alterations that occur in lipid 
raft and cellular signaling in Fabry disease.   
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3.0  GENERATION OF FABRY DISEASE HUMAN KIDNEY CELL LINES USING 
CRISPR/CAS9 GENOME EDIITING 
3.1 INTRODUCTION 
The use of experimental models in translational research, including naturally occurring and 
transgenic animals, has provided novel insights for a variety of Mendelian and complex 
disorders. Disease models serve as key tools for enabling a better understanding of disease 
pathophysiology, identification of diagnostic and prognostic biomarkers and drug discovery. 
With the exponential advances in genome technologies and computational approaches, several 
model biological species have their genome fully sequenced and at least partially annotated, 
allowing for more comprehensive studies of comparative gene function [236]. Mice are the 
most commonly used model organism in biomedical research and share 85% of similarity in 
their gene coding regions with humans [237]. These animals can be easily maintained under 
controlled, standardized environment, minimizing confounding factors. They also share several 
aspects of their anatomy, physiology and metabolism with humans but with an accelerated 
lifespan, allowing for cost-effective translation to understand human biology. However, some 
mouse models fail to reproduce full spectrum of the disease, rendering them unsuited for the 
study of certain conditions, such as Fabry disease [101]. 
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The use of human cell models in translational research has been of particular benefit 
when studying cell-type and species-specific disease phenotypes and has the additional 
advantage of allowing high throughput profiling and screening. The discovery and 
characterization of post-transcriptional gene silencing techniques have allowed their 
applications for targeted gene function studies and disease modeling in human cells. RNA 
interference (RNAi), for instance, is a highly evolutionary conserved system that provides 
protection against double-stranded RNA (dsRNA) viruses and transposons as part of a primitive 
immune response, first described in Caenorhabditis elegans [238]. These dsRNAs are cleaved 
into small interfering RNA (siRNA) and incorporated into a multiprotein-RNA complex termed 
RNA-induced silencing complex (RISC). Activated RISC-siRNA complex then recognizes 
complementary mRNA, triggering sequence-specific cleavage, destabilization or translational 
repression of the targeted mRNA and thus gene silencing [239]. Synthetic small siRNA 
molecules can be designed to target mRNA of a gene of choice and delivered into the cells for 
RISC loading, allowing for targeted gene silencing. While effective decrease in abundance of 
the targeted protein can be achieved in many instances, this system only allows for a transient 
silencing, as the majority of synthetic siRNA is degraded within 48 h [240], making this 
technique challenging to study the knockdown of proteins with low turnover/prolonged half-
life. An alternative is the use of vector based short hairpin RNA (shRNA), which allows for 
stable expression and greater knockdown efficiency, but at the cost of potential off-target effects 
since genomic integration preferably takes place in coding or promoter regions of the genome 
[239, 241].  
Morpholinos have also surged as a technique for mRNA targeted post-transcriptional 
gene silencing. These antisense oligomers bind to complementary mRNA, blocking their 
 60 
translation or affecting pre-mRNA splicing. Due to their structure, Morpholinos are particularly 
resistant to endonuclease digestion; they contain 25 synthetic subunits comprised of a nucleic 
acid base and a morpholine ring, linked through a non-ionic phosphorodiamidate, being able to 
pair with complementary endogenous nucleic acid sequences with high affinity and specificity 
[242]. An important consideration that differentiates Morpholinos of their RNAi counterparts is 
that they prevent translation instead of inducing mRNA degradation, thus the location of the 
target site within the gene is important for proper action; Morpholinos targeting the 5’-UTR or 
beginning of first exon are predicted to have a higher efficiency for gene silencing [243]. A 
growing body of evidence has shown that off-target effects can be quite significant with the use 
of the use of mopholinos in the generation of disease models or in genetic screening studies in 
zebrafish, reinforcing the importance for proper monitoring of these effects and validation of 
results generated using this approach [244]. 
Despite the enormous progress achieved by applying post-transcriptional gene silencing 
in modeling diseases at the cellular level, these techniques present some important limitations. 
For instance, incomplete blockage of gene expression of a particular gene might fail to decrease 
protein expression to achieve total abundance that is low enough to induce a phenotype. These 
factors have led researchers to search for strategies that directly manipulate the genome instead 
for stable and more pathophysiologically relevant models [245]. Artificial chimeric proteins 
comprised of DNA binding modules and endonuclease catalytic domains have been engineered 
to modify the genome by the introduction of targeted double-stranded breaks (DSBs) at specific 
genomic loci. DSBs trigger the action of the cell’s DNA repair machinery, of which non-
homologous end joining (NHEJ) or homology-directed repair (HDR) are the most common 
[246]. In an attempt to correct the DSB in the absence of a template DNA, error-prone NHEJ 
 61 
induces small frame-shifting insertions or deletions, which result in gene disruption. The first 
class of these programmable nucleases, zinc-finger nucleases (ZFN), consists of a FokI nuclease 
domain and zinc-finger modules designed to bind specific DNA sequences [247]. TALENs 
(transcription activator-like effector nucleases), another class of programmable nucleases, also 
contain a FokI nuclease domain but instead they are fused to a transcription activator-like 
effector (TALE).  ZFN can induce both deletions and insertions, while TALENS preferentially 
induce deletions [248]. However, both techniques are quite costly and can also have off target 
effects that are particularly difficult to predict during the design phase.  
More recently, a technology that employs RNA-guided endonucleases for targeted 
genome editing by repurposing the naturally occurring system of Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR) DNA loci and their CRISPR-associated 
(Cas) gene 9 (CRISPR/Cas9) has revolutionized the field of engineered nucleases. CRISPR 
DNA loci and their Cas genes provide groups of prokaryotes with adaptive immunity against 
viruses and other foreign genetic elements. These systems function by stable integration of short 
sequences from invading exogenic elements into CRISPR loci located in the genome of these 
prokaryotic cells as “protospacers”, then inducing expression of short CRISPR RNA (crRNA) 
complementary to the spacers. These loci are then transcribed into siRNAs that guide targeted 
degradation of these invading nucleic acids [249]. CRISPR-Cas systems are classified into three 
main types (I-III) and 11 subtypes (I-A to F, II-A to C, and III-A to B) according to their 
specific loci and Cas gene organization and content. Cas targeting requires the presence of a 
specific protospacer-adjacent motif (PAM) at the 3’-end, which for Cas9 is in the form of NGG. 
Type II CRISPR systems has been recently repurposed to induce targeted genome modifications 
in other organisms, including mammals [250, 251].  
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These type II CRISPR systems rely on the action of a single multi-functional protein, 
Cas9, for genome editing. In an unbound state, Cas9 is found in an auto-inhibited conformation. 
[252] Its function is then guided by binding of a dual-RNA scaffolding complex, consisting of a 
crRNA and a transactivating crRNA (tracrRNA), which have been reengineered into a chimeric 
single-guide RNA (sgRNA) that bears a 20-nucleotide target sequence. [253] Upon activation 
triggered by effective sgRNA directing and target binding, Cas9 acts as both a helicase to 
unwind the DNA duplex and as a dual nuclease, cleaving the DNA at both strands upon target 
recognition. [254] Effective directing and activation of Cas9 results in DSBs in a target genomic 
DNA sequence that complements the guide sequence in the sgRNA, which usually occurs 3 
base pairs upstream of the PAM sequence. [255] A representation of this system and main 
mechanisms of action is shown in Figure 11.  
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Figure 11: Schematic of CRISPR/Cas 9 and main applications of gene editing by engineered nucleases. 
 
Modified from [256]. 
 
I applied the CRISPR/Cas9 technique to disrupt GLA gene function in immortalized 
human podocytes and in human proximal epithelial cells. GLA gene abnormalities in humans 
cause Fabry disease, an X-linked lysosomal storage disorder characterized by alpha-
galactosidase A (α-gal A) deficiency and accumulation of its substrates, mainly 
globotriaosylceramide (Gb3). To date, the Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk) describes over 600 mutations in the human GLA gene that cause 
Fabry disease. These mutations affect the synthesis, folding, stability, substrate binding or 
action of alpha-galactosidase A, all culminating in low or absent enzyme activity in the 
lysosome. [257] Small deletions in both of the exons we targeted have been shown to cause the 
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classic phenotype of Fabry disease in patients. [258] This disease often complicates with 
nephropathy, which can culminate in complete loss of kidney function [259]. Progressive 
podocyte and tubular epithelial cell dysfunction are major components of Fabry disease 
nephropathy [260, 261]. Pathologically, this nephropathy is characterized by renal cell 
inclusions, focal segmental glomerulosclerosis, followed by progressive tubulointerstitial 
disease and decline in kidney function. [262] The renal response to enzyme replacement therapy 
is suboptimal, and the progression of nephropathy, including worsening of foot process 
effacement, can occur despite long-term treatment [263].  Little is known about the disease 
mechanisms leading to renal cell injury and death, and as Fabry disease mice do not show the 
classic signs of the kidney dysfunction seen in patients with the condition, cell-type specific 
human models of the disease are critical. 
With the assistance of an RFP/Hygromycin-GFP surrogate reporter plasmid, I was able 
to successfully achieve concurrent editing of two different coding regions of the GLA gene, 
generating kidney cell line knockouts for in vitro studies. As expected, GLA knockout cells 
exhibited the Fabry disease biochemical phenotype, characterized by reduced α-gal A enzyme 
activity and increased Gb3. These kidney cell lines may serve as tools for better understanding 
the pathogenesis of Fabry nephropathy as well as for drug discovery. 
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3.2 MATERIALS AND METHODS 
3.2.1 Culture of kidney cell lines 
Human proximal tubule cells HK-2 [264] were cultured in DMEM/F-12 medium (Gibco) 
supplemented with 10% heat-inactivated FBS (30 min at 56oC), 20mM HEPES buffer, 2mM L-
glutamine, 1% (v/v) Insulin-Transferin-Selenium (Gibco), 5 μL of and 0.4 μg/mL of 
hydrocortisone, 5 μL of triiodothyronine 20 μg/ml in NaOH, 1% (v/v) Pen/Strep (10,000 
units/mL, Gibco). Immortalized human podocytes were a gift of Dr. Jean Daniel Sraer, 
INSERM, France to Kunimasa Yan Kyorin University School of Medicine, Japan, and were 
provided by Dr. Agnieszka Swiatecka-Urban, Children’s Hospital of Pittsburgh. Isolation and 
characterization of this SV40 large T antigen immortalized cell line is described in [265]. Cells 
were cultured in DMEM/F-12 medium (Gibco) supplemented with 10% heat-inactivated FBS 
(30 min at 56oC), 2mM L-glutamine, 1% (v/v) Insulin-Transferrin-Selenium (1mg/mL, 0.55 
mg/mL and 0.67 µg/mL respectively, Gibco), and 1% (v/v) Pen/Strep (10,000 units/mL, Gibco). 
Podocytes were used for CRIPSR/Cas9 experiments between passages 13 and 17 from the 
originally immortalized cells. Cells were maintained at 37oC and 5% CO2 in a humidified 
incubator, passaged at 1:10 when they reached 80% confluence and frozen in FBS containing 
10% DMSO at -80oC or in liquid nitrogen for longer-term storage.   
3.2.2 Oligonucleotide Design 
Target sequences against the first, third, and last exons of GLA (i.e. exons 1, 3 and 7) were 
selected using bioinformatics tools. The first sgRNA used was against exon 7 and was selected 
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from a database of predicted sequences listed by Mali et al [250]. The sgRNA against exon 1 
was designed using the CRISPR Design Tool of Zhang and colleagues (http://crispr.mit.edu). 
Other sgRNAs were designed using the E-CRISP design tool under medium stringency 
parameters [266]. The experiments described herein were performed with guides 1 (against 
exon 7, R2) and 4 (against exon 1, R1). For the pX330 CRISPR/Cas9 vector (see below), 
sgRNA R1 and R2 oligonucleotide sequences were checked to confirm the absence of BbsI 
enzyme sites (i.e. GAAGAC or GTCTTC) using BLAST (NCBI). To clone the target sequences 
into the pX330 backbone after digestion with BbsI, CACCG was added to the beginning of the 
5’ region of the forward oligonucleotide, and AAAC was added to the beginning of the 5’ 
region of the reverse oligonucleotide, with a C following the target sequence at the 3’ end, 
excluding the PAM sequence. Standard desalted oligos were purchased from Integrated DNA 
Technologies. Primer sets flanking the target regions of the GLA gene were designed using 
NCBI Primer Designing Tool under default settings, blasting against the Homo sapiens 
reference genome database (refer to Table 2 for primer sequences). Preference was given to 
product sizes between 600 and 1200 to allow for better separation and visualization of T7 
Endonuclease 1 (T7E1) digestion products on a 2% agarose gel.  
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Table 2: Oligonucleotides and primers used in this study. 
 
3.2.2.1 Region Plasmid 3.2.2.2 Sequence 5’- 3’ 
3.2.2.3 R1 (exon 1) 
3.2.2.4 pX330 3.2.2.5 F: CACCGATAAATTTCCGCGGGTAACC 
3.2.2.6 R: AAACGGTTACCCGCGGAAATTTATC 
3.2.2.7 pHRS 3.2.2.8 F: AATTCTCCAGGTTACCCGCGGAAATTTATAGGAG 
3.2.2.9 R: GATCCTCCTATAAATTTCCGCGGGTAACCTGGAG 
3.2.2.10 PCR 3.2.2.11 F: ACGGCTATAGCGAGACGGTA R: GGGTCTGAATAGAACCGGGC 
3.2.2.12 R2 (exon 7) 
3.2.2.13 pX330 3.2.2.14 F: CACCGTGTGGGAACGACCTCTCTC 
3.2.2.15 R: AAACGAGAGAGGTCGTTCCCACACC 
3.2.2.16 pHRS 3.2.2.17 F: AATTCTGTGTGGGAACGACCTCTCTCAGGAGGAG 
3.2.2.18 R: GATCCTCCTCCTGAGAGAGGTCGTTCCCACACAG 
3.2.2.19 PCR 3.2.2.20 F: GACCAGGGGGTTGGAATGAC 
3.2.2.21 R: AGCTGAAGCAAAACAGTGCC 
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3.2.3 Plasmid Generation 
pHRS vector was purchased from PNA Bio Inc. The pHRS plasmid works as a surrogate 
reporter of CRISPR/Cas9 activity. It contains an expression cassette for mRFP, an 
oligonucleotide sequence containing a stop codon flanked by EcoRI and BamHI digestion sites, 
and a hygromycin selectable marker linked to GFP separated by a self-cleaving 2A peptide. In 
the unedited state, translation of reporter cassette stops after the mRFP and target region due to 
the presence of a stop codon. Upon cloning of oligonucleotide containing the target sequence of 
interest in the genome, CRISPR/Cas9 modification by the engineered nuclease induces a 
double-strand break in the target region, resulting in non-homologous end joining and 
introduction of insertion and/or deletion mutations in the plasmid. This frequently eliminates the 
stop codon by frame shifting the plasmid DNA, conferring translation of hygromycin resistance 
and GFP [267]. The same oligonucleotide guide sequences designed for the pX330 
CRISPR/Cas9 plasmid were used for the pHRS reporter plasmid, with inclusion of respective 
PAM sequence for nuclease binding and activation. Reporter function was simulated in silico 
for frame shifting and loss of stop codon after indels are inserted into target region using Vector 
NTI Software (Life Technologies). Overhangs for EcoRI (AATTCT) were added to the 5’ end 
of the plus strand, GA to the 3’end of the minus strand, as well as a G to the 3’ end of the plus 
strand sequences. Additional residues necessary to maintain the reading frame of the plasmid 
were added as needed upon simulation using Vector NTI. Standard desalted oligos (refer to 
Table 2 for pHRS oligo sequences) were purchased from Integrated DNA Technologies. Each 
pair of complementary oligonucleotides for either pX330 or pHRS incorporation was 
phosphorylated and self-annealed for proper ligation (100 µM per single oligonucleotide) using 
T4 polynucleotide kinase (PNK) and T4 ligation buffer (New England BioLabs) according to 
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the manufacturer’s protocol. Thermocycler settings were as follows: 37oC for 30 min, 95oC for 
5 min, then ramping down to 25oC at 5oC/min.  
The pHRS plasmid was digested with EcoR1-HF (New England Biolabs) and BamH1-
HF (New England Biolabs) in CutSmart Buffer (New England Biolabs) for 30 min at 37oC. Gel 
purification was performed in 1% agarose gel using Wizard SV gel and PCR Clean-Up System 
(Promega) according to the manufacturer’s protocol. Phosphorylated and annealed oligo 
duplexes (1:250 dilution) were then ligated into purified digested vector using T7 DNA ligase 
(New England BioLabs), incubated at ambient temperature for 30 min according to the 
manufacturer’s protocol.  
For the pX330 plasmid, settings for cloning of phosphorylated and annealed oligos into 
the backbone vector were optimized, and were performed as a single-step digestion ligation 
reaction as follows: pX330, 100 ng; oligo duplex, 1:250 dilution, 2 µL; Tango buffer (Thermo 
Scientific), 2µL; DTT 10 mM, 1 µL; ATP, FastDigest BbsI (Thermo Scientific), 1 µL, T7 DNA 
ligase (New England Biolabs), 0.5 µL and DEPC-treated H2O, qsp 20 µL.. Thermocycler 
settings were as follows: 37oC for 5 min, 23oC for 5 min, cycling these two steps 6 times for a 
total run time of 1 h. In order to prevent unwanted recombination products, ligation reactions 
for both pHRS and pX330 vectors were treated with PlasmidSafe ATP-depended DNase 
(Epicentre) for 30 min at 37oC according to the manufacturer’s protocol. Ligation products (2 
µL) were transformed into One Shot® Stbl3™ Chemically Competent E. coli (Thermo Fischer 
Scientific) according to the manufacturer’s protocol. Transformation products (25 µL or 100 
µL) were seeded onto ampicillin (pX330) or kanamycin (pHRS) LB agar plates. Individual 
colonies were grown in LB broth solution with 1:1,000 ampicillin (100 mg/mL stock 
concentration) for pX330 or 1:1,000 kanamycin (50 mg/mL stock concentration) for pHRS. 
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Plasmid isolation and purification was performed using QIAprep spin Miniprep Kit (Qiagen) 
and QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturer’s protocol. Vector 
clones sequences were confirmed for oligo incorporation using Sanger Sequencing performed 
by the University of Pittsburgh Genomics Research Core using the hU6  and pCMV forward 
sequencing primers for pX330 and pHRS respectively. Oligo incorporation into vectors was 
confirmed using CLC Genomics Workbench (Qiagen). A representation of the plasmids used 
can be found in Figure 12. 
Figure 12  
Figure 12: Plasmids used in this study. 
A. pX330 CRISPR/Cas9 plasmid and B. pHRS surrogate reporter plasmid and its mechanism of action. 
Hyg-eGFP: hygromycin-eGFP.  
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3.2.4 Plasmid Delivery  
Approximately 5 x 105 cells were seeded in 6-well plates with 2 µg of pX330 plasmid and 
immediately transfected with 2 µg of the corresponding pHRS plasmid per well using 4 µL of 
lipofectamine 3000 (Invitrogen), 10 µL of P3000 reagent and 1 mL of OptiMEM following the 
manufacturer’s instructions. For concomitant delivery of pX330 and pHRS plasmids targeting 
the two different regions of GLA, 1 µg of each plasmid was used to transfect 5 x 105 cells, for a 
total of 4 µg of DNA. Transfection of empty pX330 and pHRS vectors was used as control. 
Growth medium was changed after 12 h and experiments were performed 48 to 72 h after 
transfection.  
3.2.5 Fluorescence-Activated Cell Sorting 
Approximately 1.5 x 106 cells co-transfected with pX330 and pHRS were trypsinized with 
TrypLE™ Select (Thermo Fischer Scientific) for 5 min, centrifuged at 500 x g for 3 min and re-
suspended in 600 μL of PBS supplemented with 10% BFS. To achieve a single-cell suspension, 
cells were passed through 50-μm filcon filters (BD Biosciences). Single-cell suspensions were 
analyzed and sorted in a BD FACSAria II (BD Biosciences), with FACSDiva version 6.1.3 
software. Default setup was applied for RFP and GFP fluorescence detection (For GFP: 488-nm 
blue laser, E PMT, 502 LP mirror, 430/30 BP filter; for RFP: 488-nm blue laser, D PMT, 556 
LP mirror, 585/42 BP filter). RFP/GFP double-positive cells were collected into 96-well dishes 
for clonal populations and/or into 15 mL conical tubes, both containing specific growth 
medium.  Gating for GFP and RFP fluorescence was performed using untransfected cells and 
cells transfected with empty pHRS and pX330 vectors as controls. 
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3.2.6 Hygromycin Treatment 
A hygromycin selection dose-response curve in human immortalized podocytes and HK-2 cells, 
yielded 2 mg/mL as the optimal hygromycin concentration for rapid (48 h) toxicity to the 
majority of cells for both cell types. For hygromycin selection, 5 x 105 human immortalized 
podocytes or HK-2 cells were treated 48 h after co-transfection with pHRS and pX330 plasmids 
with 2 mg/mL of Hygromycin B (Invitrogen) in growth medium. After 48 h, the drug was 
removed and the remaining viable cells were cultured in growth medium until further 
characterization.  
3.2.7 Genomic DNA extraction and PCR amplification 
Genomic DNA from approximately 1x105 cells was extracted using QuickExtract DNA 
extraction solution (Epicentre) according to the manufacturer’s protocol. Briefly, cells were 
pelleted in a microcentrifuge tube at 800 g for 3 min, washed once in 1X PBS, Dulbecco's 
Solution minus Mg2+ and Ca2+, and lysed by vortexing for 15 s in 500 µL of DNA extraction 
solution. Lysates were then incubated at 65oC for 6 min, vortexed for 15 s and then incubated at 
98°C for 2 min and stored at -20oC until further use. The genomic region flanking the 
CRISPR/Cas9 target sites were amplified by PCR using Phusion® High-Fidelity DNA 
Polymerase (New England BioLabs) using 5 μL of extracted genomic DNA as a template. A 
touchdown approach was applied for enhanced specificity and yield [268]. The following 
settings were applied: 30 s at 98°C, 15 cycles at [98°C for 10 s, 67°C for 30 s (reducing 
annealing temperature by 1°C each cycle), 72 °C for 30 s], followed by 25 cycles at [98 °C for 
10 s, 52 °C for 30 s, 72°C for 30 s], and a final cycle of 72°C for 10 min. PCR products were 
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separated in a 2% agarose gel stained with SYBR® Safe DNA Gel Stain (Thermo Fischer 
Scientific) and visualized on a Molecular Imager® Gel Doc™ XR System (Bio-Rad 
Laboratories, Inc.). Images were processed using Image Lab™ 5.1 Software (Bio-Rad 
Laboratories, Inc.). 
3.2.8 T7 Endonuclease I Assay 
Amplicons were hybridized by denaturing and re-annealing to allow for homo- and 
heteroduplex formation. Briefly, 1.6 µg of PCR products were resuspended in a final volume of 
10 µL in 1x Phusion High Fidelity PCR buffer (New England Biolabs) and duplicate samples 
amplified in a thermocycler using the following settings: 95oC for 10 min, then ramp down to 
85oC, decreasing at 2.0oC/s. After that, the temperature was dropped 10oC at a time at a rate of 
0.3oC/s, maintaining target temperatures for 1 min until reaching 25oC. Hybridized products do 
you just mean the final reactions? were stored at 4oC until further use. Hybridized products were 
then digested with T7 Endonuclease I (T7E1) (New England BioLabs) at 37oC for 15 min. 
Digested products along with undigested hybridized products were separated on a 2% agarose 
gel and scanned on a Molecular Imager® Gel Doc™ XR System (Bio-Rad Laboratories, Inc.). 
Images were processed using Image Lab™ 5.1 Software (Bio-Rad Laboratories, Inc.).  
3.2.9 Immunofluorescence 
For human immortalized podocytes, 2.5 x 104 cells were seeded on coverslips coated with 10% 
PureCol® type I bovine collagen solution (Advanced BioMatrix) in growth medium in 12 well 
cell culture dishes. After 24 h, coverslips were fixed with 10% neutral buffered formalin 
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solution (Sigma-Aldrich) for 15 min, quenched for 5 min in 50 mM NH4Cl and 0.1M glycine in 
PBS and permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in quench solution for 8 min. 
The samples were then blocked for 1 h in 1% BSA (Sigma-Aldrich) and 0.1% saponin (Sigma-
Aldrich) in PBS. Next, the coverslips were incubated with primary antibodies [anti-CD77 
(Ab35768 rat monoclonal IgM, Abcam)] for 1 h then washed twice quickly with PBS followed 
by washing 3 times for 5 min in PBS containing 0.5% BSA (Sigma-Aldrich) and 0.05% saponin 
(Sigma-Aldrich) in a shaker. Coverslips were then incubated with secondary antibodies (Cy3 
goat anti-rat IgM; Alexa Fluor 488 goat anti-rat IgM) for 30 min. All steps were performed at 
ambient temperature. The cover slips were mounted on slides with ProLong Gold Antifade 
Reagent with DAPI (Invitrogen). Images were captured using a Leica DM6000 B fluorescence 
upright microscope system (Leica Microsystems) and processed using Volocity 6.1 Software 
(PerkinElmer). 
3.2.10 Enzyme Activity Assay 
Alpha-galactosidase A activity was measured fluorimetrically in control and CRISPR/Cas9 
modified (Fabry) immortalized human podocytes and HK-2 cells using 4-methylumbelliferyl-α-
D-galactopyranoside (Sigma) as the substrate. Approximately 106 cells were pelleted in a 
microcentrifuge tube at 800 g for 3 min, washed once in PBS, Dulbecco's Solution minus Mg2+ 
and Ca2+, and re-pelleted. Cells were then lysed by 3 cycles of freeze-thaw in 500 µL of citrate-
phosphate buffer (50 mM citric acid monohydrate, 100 mM dibasic sodium phosphate-
anhydrous, pH 4.8), vortexing for 15 s between freeze cycles. Protein concentration was 
measured using a BioPhotometer (Eppendorf) using the protein direct photometric measurement 
setting at 280 nm. Equal amounts of protein were used to measure enzyme activity. Lysates (50 
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µL) were incubated with 20 µL of substrate solution (5 mM 4-methylumbelliferyl-α-D-
galactopyranoside (Sigma-Aldrich) and 100 mM N-acetylgalactosamine (Sigma-Aldrich) in 
DEPC treated water) for various times (1 h at 37oC or 6 h and 24 h at ambient temperature). To 
assess linearity of the assay, four reactions were set up by mixing 0, 5, 25, or 50 µL of lysate of 
control cells with of 50, 45, 25, or 0 µL of lysate that underwent boiling at 100oC for 10 min for 
enzyme inactivation. These reactions corresponded to 0, 10, 50, and 100% of enzyme activity in 
control cells, respectively. Two sets of reactions were incubated with substrate solution for 1 h 
at 37oC and 24 h at ambient temperature, respectively. Enzymatic activity was terminated by 
addition of 70 µL of 50 mM glycine ammonium hydroxide, pH 10.5. The fluorescence intensity 
of released 4-methyl-umbelliferone was quantified in a GloMax®-Multi+ Detection System 
with Instinct® Software at excitation 360-380nm/ emission 500nm. 
3.3 RESULTS 
3.3.1 CRISPR/Cas9 mediated editing of GLA in human immortalized podocytes and HK-
2 cells 
Progressive kidney dysfunction is a major clinical finding of the X-linked lysosomal storage 
disorder Fabry disease. [262] To model Fabry disease nephropathy in vitro, I created two 
genome edited renal cell lines: human immortalized podocytes and HK-2 cells, a human 
proximal epithelial cell line. While a variety of renal cell types can be affected in Fabry disease, 
involvement of podocytes and tubular epithelial cells is a typical and early finding of 
nephropathy in these patients. [261, 263] 
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Using bioinformatics tools, I selected two sgRNAs against the first and seventh exons of 
the human GLA gene and cloned them into the pX330 plasmid. The sequences of the 
oligonucleotides used in this study are listed in Table 2. I first delivered CRISPR/Cas9 pX330 
plasmids targeting the GLA exon 7 or empty pX330 plasmids as control to human podocytes 
and HK-2 cells using lipid-mediated transfection. Next, I enriched for cells with CRISPR/Cas9-
induced modifications by co-transfection with the surrogate reporter plasmid pHRS. This 
plasmid contains cassettes for mRFP expression, the same CRISPR/Cas9 genome target 
nucleotide sequence, (including the PAM for Cas9 recognition) and for an eGFP-hygromycin 
resistance fusion protein. This plasmid is designed so that mRFP is expressed constitutively 
whereas the eGFP and hygromycin genes are out-of-frame and preceded by a stop-codon and a 
self-cleaving 2A peptide. In the absence of plasmid editing, mRFP will be expressed but 
transfected cells will lack eGFP expression and hygromycin resistance. Double-stranded breaks 
at the target sequence of the plasmid by CRISPR/Cas9 and subsequent non-homologous end 
joining repair causes a frameshift, which enables eGFP expression and hygromycin resistance 
[267]. This provides two straightforward approaches (FACS and drug resistance) to enrich for 
gene-edited cell populations, as modification of this reporter plasmid mirrors genomic 
modification in the cells at least partially [267]. Forty-eight hours after co-transfection of 
plasmids into both immortalized podocytes and HK-2 cells, 4-10% of cells expressed mRFP, 
demonstrating moderate transfection efficiency of the reporter plasmid. A small proportion of 
the mRFP positive cells also were positive for eGFP fluorescence by FACS, indicating that 
frameshifting indel changes were incorporated into the reporter plasmid, inducing translation of 
eGFP. The efficiency of plasmid modification, characterized by eGFP expression, varied from 
15 to 18%, corresponding to 0.8 to 1.6% of the starting population (data not shown).  
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For HK-2 cells, mRFP/eGFP double positive CRISPR/Cas9 GLA treated cells or mRFP 
positive for control cells were FACS sorted, collected, and clones expanded from single cells in 
96-well dishes. As human immortalized podocytes are particularly sensitive to cell sorting and 
are difficult to grow from single cells, mRFP/eGFP double positive CRISPR/Cas9 GLA treated 
cells or RFP positive control cells were instead cloned by limiting dilution and plated in 15 cm 
dishes. Next, I assessed genomic level GLA modification in a mixed population of FAC sorted 
cells using the T7 Endonuclease 1 assay. Endonuclease I of phage T7 (T7E1) is a highly 
selective enzyme that introduces paired cleavages in Holliday junctions, which are four-way 
branched DNA structures that can be formed by double-strand break (DSB) repair [269]. The 
endonuclease T7 I assay was recently reported to be the preferred method to assess for genomic 
changes induced by engineered nucleases [270]. This paralleled my own experience that T7EI 
was more sensitive in showing editing in mixed cell populations. T7E1 assay of hybridized 
amplicons flanking the target region demonstrated cleavage of PCR products with bands of the 
expected product size. These bands were only present in CRISPR/Cas9 GLA treated cells, 
suggesting successful modification of GLA gene in both HK-2 and podocyte populations 
(Figure 13).  
Of note, for one of the clonal podocyte populations of CRISPR/Cas9 GLA treated 
podocytes, initial analysis of PCR amplicons flanking target GLA region by gel electrophoresis 
revealed a large deletion, which was confirmed by Sanger sequencing. However, I observed a 
progressive drift back towards the unmodified amplicon over successive passages. This 
phenomenon was not observed in Hk-2 clonal cell populations, which, even after three months 
of continuous passage, have maintained the genomic modification and Fabry disease phenotype.  
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The initial mixed FACS population plus additional three clonal cell populations of 
podocytes, including an earlier passage of the clone that showed drifting, then underwent a 
second round of CRISPR/Cas9 treatment, this time with co-transfection of pX330 plasmids 
targeting both exons 1 and 7 and respective pHRS reporter plasmids. As pHRS plasmid induces 
expression of both GFP and hygromycin, I opted during the second round of CRISPR/Cas9 
treatment to perform enrichment using hygromycin as described in Methods.   
After the second round of CRISPR/Cas9 treatment in mixed populations of 
immortalized human podocytes, T7E1 assay of PCR amplifications flanking targeted regions of 
showed additional bands present only in the CRISPR/Cas9 GLA treated cells, again suggesting 
successful genome editing of both targeted regions. Interestingly, PCR analysis flanking the 
target region in exon 1 demonstrated the presence of amplicons significantly larger and smaller 
in size in all CRISPR/Cas9 GLA podocyte cell populations, suggesting generation of larger 
indels. PCR amplicons and T7E1 assay for HK-2 clone and podocyte mixed populations can be 
seen in Figure 13. 
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Figure 13: Amplicons and T7 endonuclease I assay of GLA gene region flanking the CRISPR/Cas98 genomic 
target in HK-2 cells and podocytes. 
 
Panel A. PCR and T7E1 assay in control (CTRL) and CRISPR/Cas9 GLA podocyte cell populations (P1-
P4). Panel B. PCR and T7E1 assay in control (CTRL) and HK-2 CRISPR/Cas9 GLA clone (H1). Hyb: 
hybridized amplicon heteroduplex. 
 
These data are consistent with what Brandl et al. [271] observed when simultaneously 
targeting two different coding regions of Rab38 in embryonic stem cells. They report that 
multiplex targeting for a same gene can result in larger deletions as well as non-canonical 
chromosomal rearrangements in at least one of the alleles.  
 80 
3.3.2 Phenotypic characterization of CRISPR/Cas9 edited cells 
Loss of function mutations in the GLA gene associated with Fabry disease result in α-gal A 
deficiency, with inability of the enzyme to metabolize neutral glycosphingolipids with α-D-
galactosyl residues, mainly globotriaosylceramide (Gb3/CD77). To assess the phenotype of the 
generated kidney cell lines, enzyme activity and anti-CD77 staining were performed.  We found 
no detectable α-gal A enzyme activity assay in CRISPR/Cas9 GLA edited HK-2 clonal cell and 
podocyte mixed cell populations (Figure 14), with preserved activity of α-mannosidase, a 
lysosomal hydrolase that cleaves mannoside residues of glycoproteins [272].  
 81 
  
Figure 14: Decreased α-gal A enzyme activity in podocytes and HK-2 cells genome modified for Fabry 
disease. 
 
Fluorometric enzyme activity assay for α-gal A using 4-MU substrate in human immortalized podocytes 
(A) and HK-2 cells (B) that undergone CRISPR/Cas9 treatment at the GLA gene. 
 
Next, we examined Gb3 levels in CRISPR/Cas9 GLA edited cells. In Fabry disease, Gb3 
is known to progressively accumulate in kidney cells, a process that can begin in utero and 
which results in tissue damage, often culminating in kidney failure. [273] Anti-CD77 
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immunofluorescence staining of both podocytes and HK-2 cells revealed higher levels of the 
glycosphingolipid in CRISPR/Cas9 edited podocytes and HK-2 cells, confirming a substantial 
increase in the substrate for alpha-galactosidase A in CRISPR/Cas9 GLA edited cells (Figure 
15). 
 
 
Figure 15: Globotriaosylceramide accumulation in podocytes and HK-2 cells genome modified for Fabry 
disease. 
 
Immunofluorescence staining for globotriaosylceramide (Gb3) detected using anti-CD77 antibody in 
human immortalized podocytes (upper panel) and HK-2 cells (lower panel) that undergone 
CRISPR/Cas9 treatment at the GLA gene (right panels). Control podocytes and HK-2 cells are 
represented on the left. Scale bar: 20 μm.  
 
 
Both of these biochemical methods indicate successful modeling of Fabry disease in 
human podocytes and HK-2 cell lines through CRISPR/Cas9 editing, as the generated kidney 
cells show both a deficiency in alpha-galactosidase A and accumulation of Gb3. 
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3.4 DISCUSSION 
Understanding the cellular mechanisms underlying renal cell injury in Fabry disease is crucial 
for development of novel therapies, especially when the currently available enzyme replacement 
therapies only partially slows the progression of the nephropathy.  
By applying CRISPR/Cas9 with the help of a surrogate reporter plasmid for enrichment, 
I have successfully developed kidney cell models of Fabry disease. GLA edited podocytes and 
HK-2 cells showed a dramatic reduction in α-gal A activity, coupled with an increase in Gb3, 
the main substrate of the enzyme. Both of these features are biochemical hallmarks of Fabry 
disease.  
Post-transcriptional gene silencing techniques oftentimes do not enable a reduction in 
protein abundance that yields a phenotype.  This is of particular concern in enzyme deficiencies 
such as Fabry disease, where the targeted protein has a prolonged half-life of 4 days [274] and 
where dramatic reduction of enzyme activity needs to be achieved to induce a phenotype. For 
instance, male patients with the condition present with α-gal A enzyme activities that typically 
range between 0 and 10% of normal [85].  
Genome editing techniques are excellent alternatives for effectively modeling diseases 
when stable complete loss of function is desirable. CRISPR/Cas9 confers a superior alternative 
to TALENs and ZNFs due to its simplified design, easier prediction, potentially higher 
efficiency and lower cost. In addition, unlike their genome-editing counterparts, CRISPR/Cas9 
can cleave methylated DNA, expanding editing capability. [275] 
The majority of CRISPR-Cas9 editing efficiently generates loss-of-function alleles. 
[276] For autosomes in diploid cells, CRISPR/Cas9 induces DSB and consequently NHEJ 
independently in each allele, thus heterozygous changes are more likely than homozygous 
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modifications. [277] Therefore, modeling X-linked conditions such as Fabry disease in male 
cell lines has a higher probability of success.  
However, some caveats regarding the use of CRISPR/Cas9 should be considered. As 
this is a relatively novel technique, guide design algorithms are constantly evolving, especially 
as we learn more about features that affect target efficiency such as sgRNA sequence and size, 
target GC content, exon location, presence of higher order chromosomal structures and 
accessibility to chromatin as well as Cas9-RNA interaction motifs. [276, 278, 279] The 
prediction algorithms currently available may apply different design and scoring systems, 
yielding different sgRNA recommendations with little or no overlap. This makes it challenging 
for researchers to proper select their sgRNAs. In addition, cell-type-specific and genomic-
specific differences can be found in chromatin modification and conformation as well as 
accessibility to nucleases, resulting in variations in targeting efficiency that are difficult to 
predict. [278, 280]  
Furthermore, recent studies have attempted to better understand CRISPR/Cas9 
specificity using genomic approaches. [281, 282] As for other genome editing techniques, 
besides the intended gene of interest, other highly homologous coding and non-coding regions 
of the genome can also be targeted and cleaved by CRISPR/Cas9 with same efficiency as for 
intended targets, even in regions with a significant number of mismatches, leading to undesired 
off-target genome editing. [283] Several strategies in sgRNA and Cas9 design, modification and 
delivery have then been applied in an attempt to reduce off-target effects [284, 285] 
Bioinformatics algorithms predict off-target sites with varying accuracy based on sequence 
alignment against the reference genome, however, the magnitude of off-target effect varies 
greatly per site, regardless of numbers of mismatches. [278, 286] Thus, these tools need to be 
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more extensively assessed for efficacy and their results properly validated. In addition, off-
target prediction can be particularly challenging when working with cell lines; cells in culture 
can undergo increasing number of genomic changes, including copy number variations, loss of 
heterozygosity and aneuploidies, making it difficult to anticipate the presence and consequences 
of off-targeting. [287, 288]  
Obtaining efficient plasmid delivery with low cell toxicity is a challenge when working 
with several immortalized cell lines, and this was the case for our human immortalized 
podocytes. These cells required a longer recovery time after being sorted by FACS, even when 
transfected with empty vectors alone. In addition, we observed cell-type dependent drifting 
towards unmodified cells in CRISPR/Cas9 GLA treated immortalized human podocytes. This 
drifting was not observed in our HK-2 cell populations. Differences in the cell cloning 
approaches/requirements might have played a role in this phenomenon. For cells that can 
tolerate sorting by FACS and individual seeding in 96-well plates, this might represent a s 
uperior strategy for obtaining pure stable clonal cell populations. Furthermore, the drifting 
observed might indicate a significant survival or proliferation advantage of unmodified over 
GLA edited podocytes. These differences in cell viability and/or proliferation among GLA 
edited and control podocytes would not be surprising given that human podocytes are 
particularly sensitive to α-gal A deficiency.  
3.5 CONCLUSION 
Despite some limitations, cell models of disease can be extremely useful tools for understanding 
disease mechanisms and cell-type specific gene function. These models can be particularly 
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helpful in cases where disease cannot be properly replicated in other animals and can be easily 
applied for high throughput biomarker and drug discovery. CRISPR/Cas9 can induce efficient, 
stable, pathophysiologically relevant targeted genome modifications, which can be employed 
for hypothesis generating and testing in the study disease mechanisms in vitro.  
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4.0  HIGH THROUGHPUT PHOSPHORYLATION PROFILING OF A HUMAN 
PODOCYTE CELL MODEL OF FABRY DISEASE 
4.1 INTRODUCTION 
High-throughput approaches in cell biology allow for rapid unbiased generation of large 
amounts of data that can be used to understand a variety of cellular processes in health and 
disease as well as to generate and test novel hypotheses in disease pathophysiology, allowing 
for biomarker discovery and drug development.   
Several techniques are currently used for high-throughput analyses of mRNA 
expression, including hybridization- and sequence-based approaches. Microarrays are based on 
principles of Northern or Southern blot analyses, in which mRNA or cDNA labeled with a 
fluorescent dye hybridizes to probes that are covalently spotted onto an inert surface (namely a 
glass slide or a microchip) [289]. Fluorescence for each spot is then measured and processed 
using a fluorescence laser scanner and computational tools. This value of measured fluorescence 
for each spot is directly proportional to the amount of bond fluorescently labeled mRNA/cDNA. 
While these techniques do not provide information on absolute abundance of a particular 
mRNA in a given sample, they do allow for comparative analysis of the expression level among 
genes or conditions (healthy control vs. disease). Microarray analysis results can then be applied 
in class comparison, class prediction or class discovery [290]. Microarrays are relatively 
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inexpensive and straightforward techniques, but they have some limitations. Analysis is limited 
to the probed targets in the specific microarray being used, thus can only be performed on 
known (and properly probed) mRNAs/cDNAs, limiting the discovery of novel transcripts or 
splicing forms. In addition, the presence of a background noise and the saturability of 
fluorescence signals limit the dynamic range of this technique for targets with very low or very 
high expression. Probes are also potentially susceptible to cross-hybridization, allowing for 
false positive results. Furthermore, the analysis depends on the quantitation of fluorescence 
signals in a scanned image of a slide/chip, which needs to be properly preprocessed and 
normalized, adding an extra level of complexity.  
The sequence-based methods of RNA sequencing allow for detection and precise 
quantification of both common and rare transcripts, novel isoforms and gene fusions, all at the 
single base resolution and virtually no background noise [291]. While several different 
protocols can be employed depending on the platform used, they usually share the principle of 
reverse transcription of total RNA into a cDNA library, which is then fragmented and processed 
[292]. cDNA fragments are then read, assembled and mapped to a reference genome using 
computational pipelines. Estimation of expression of a transcript is then calculated as a function 
of the depth (i.e. number of read counts) normalized to length of the transcript, in the form of 
reads per kilobase of exon model per million mapped reads (RPKM) [293]. However, this 
technique also presents some important limitations. As with genome/exome deep-sequencing 
counterparts, RNA sequencing coverage varies across transcripts and ambiguity may hinder 
mRNA mapping, since short transcripts can often be matched to several regions of the reference 
genome [291]. Furthermore, considerable variation in expression level estimates can be seen 
when applying different RNA-seq methodologies [294].   
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Furthermore, the central dogma of molecular biology, which states that “DNA makes 
RNA and RNA makes protein”, actually entails much more complexity than originally thought. 
While the human genome is comprised of approximately 21,000 genes, the human 
transcriptome contains more than 80,000 protein-coding transcripts, which are estimated to 
translate into 250,000 to 1 million proteins [295]. Non-coding RNAs, including microRNAs and 
small nucleolar RNAs, also play important roles in transcript modification and regulation, 
adding more to the complexity of biological systems. In addition, after translation, proteins can 
be reversibly or irreversibly modified, affecting the diversity and extension of their function 
[296]. Furthermore, the half-life of proteins also varies greatly, with several intrinsic and 
extrinsic factors contributing to protein degradation rate [297]. Thus, not surprisingly, mRNA 
expression does not always correlate with protein levels, just as not always protein abundance 
correlates with their function [298]. 
Protein modifications that modulate protein function after translation can occur through 
proteolytic cleavage or alterations to the side chains of amino acids, which include several 
enzymatic and non-enzymatic processes such as: adding of prosthetic groups (i.e. biotin, lipoate, 
panthotenate, pyridoxal phosphate and FAD), acetylation, acylation, alkylation, prenylation, 
glycosylation, sulfation, ribosylation, oxidation, hydroxylation, carboxylation, glycation, 
methylation, de- or transamidation, ubiquitination or phosphorylation [299]. 
Protein phosphorylation is the main post-translational modification by which signaling 
molecules modulate intracellular processes. This process takes place by the action of more than 
2000 upstream kinases, which add a phosphate group to the side chains of serine, threonine or 
tyrosine residues, and is reversed by a smaller number of phosphatases [300]. Phosphorylation-
dependent regulation of protein function can result in changes to protein activation, 
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transcriptional regulation, subcellular localization, protein and lipid interactions as well as 
degradation. In disease states, changes in phosphorylation status or abundance of key 
phosphoproteins result in aberrant activation or suppression of signaling. 
High-resolution mass spectrometry (MS) based proteomics allows for quantitative 
analysis of protein abundance, post-translational modifications and interactions in a broad 
dynamic range and remains the method of choice for exploratory proteome discovery [301]. MS 
is based on the detection of ionized analytes converted into a gas phase, when they then go 
through a mass analyzer. Proteins can be processed for identification in their full-length (top-
down) or from its peptides after digestion step (bottom-up). In either case, samples undergo 
several steps of enrichment and fractionation, which vary according to the biological question. 
Proteins or digested peptides then undergo separation and analysis. Each analyte has a specific 
mass over charge ratio (m/z), intensity, and retention time (RT), allowing for its precise 
detection, identification and quantification [302]. These techniques provide a very accurate and 
sensitive method for identification and quantitation of proteins in a sample. However 
proteomics methods are quite complex and involve multiple steps, which introduce sources of 
variability and hampers reproducibility of the results [303]. Functional analysis and 
interpretation of proteomic results can also be considerably challenging. While the discovery of 
novel post-translational modifications can provide novel insights regarding protein structure and 
function, validation of results using more established techniques such as Western blotting can 
be difficult due to lack of specific reagents.  
Antibody microarrays serve as alternative tools for functional, semi-quantitative analysis 
of known physiologically relevant proteins. They also allow for analysis of particular post-
translational modifications such as phosphorylation. [304] These immunoassay-based arrays 
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allow for multiplex detection and estimated quantification of hundreds of native and/or post-
translationally modified proteins in complex biological samples. Commercially available 
antibody microarrays can be found in different formats. In the most common one, specific 
antibodies against the proteins of interest are immobilized onto a solid surface (e.g. glass slides) 
where the pre-processed sample is incubated and detection is performed using a fluorescent dye. 
[305]  
Progressive loss of kidney function is a common serious complication of Fabry disease, 
an X-linked lysosomal storage disorder characterized by deficiency of alpha-galactosidase A (α-
gal A) and glycosphingolipid accumulation. Podocyte injury is a major contributor to the 
glomerulopathy seen in these patients; foot process effacement can be seen even in subclinical 
disease and oftentimes worsens despite long-term enzyme replacement therapy. [263] Little is 
known about the intracellular events triggered by increased levels of glycosphingolipids and 
how they culminate in podocyte dysfunction in Fabry disease. Several proteomic-based studies 
have been performed in Fabry disease patients either in urine [306-310], serum [311], plasma 
[312] or peripheral blood mononuclear cells [313], however none of them specifically addressed 
disease-relevant podocyte-specific changes in signaling proteins.  
Podocyte survival and function such as maintenance of the filtration barrier and of the 
glomerular basement membrane rely upon maintenance of cell homeostasis mediated by the 
action of several signaling molecules. Recent efforts have resulted in a comprehensive 
understanding of the transcriptome [314] as well as the phosphoproteome [315, 316] of 
podocytes. Exploring differences in abundance and phosphorylation of key proteins in the 
podocyte in the context of Fabry disease is crucial in improving our understanding of the 
pathophysiology of Fabry nephropathy.   
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I performed a phosphorylation profiling of immortalized human podocytes that were 
genome edited for Fabry disease and compared to control cells. Using a high-throughput 
antibody array containing 1318 antibodies covering a variety of signaling pathways crucial for 
cellular homeostasis, I measured the differential fold change for each total protein as well as 
their phosphorylation status per site in Fabry disease and control human immortalized 
podocytes. After mining data using R, I applied bioinformatics tools to select candidate 
phosphoproteins, as well as correspondent signaling pathways and gene networks. These 
analyses point to canonical pathways such as MAPK as being differentially activated in Fabry 
disease podocytes.  
4.2 MATERIALS AND METHODS 
4.2.1 Phospho-specific Antibody Microarray 
Phospho-Explorer Antibody Arrays and Antibody Array Assay Kit were obtained from Full 
Moon Biosystems. Experiments were performed according to the manufacturer’s protocol using 
solutions provided. Approximately 5x106 control and GLA edited (Fabry disease) immortalized 
podocyte cells were pelleted by centrifugation at 500 g for 2 min at 4oC, washed 3 times with 
ice-cold PBS. Proteins were extracted by adding 200 μL of non-denaturing lysis buffer and lysis 
beads to the pellet, followed by 5 cycles of vortexing for 1 min and incubating on ice for 10 
min. Lysates were centrifuged at 10,000 g for 5 min at 4oC and the supernatants were 
transferred to fresh tubes. Lysates (100 μL) were then purified using provided, previously 
hydrated affinity columns centrifuging at 750 g for 2 min. Purified lysates were frozen at -80oC 
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for 10 min and immediately centrifuged at 16,100 g for 15 min at 4oC. Lysate protein 
concentration was measured using UV absorbance spectroscopy at 280 nm using a NanoDrop 
Spectrophotometer (Thermo Scientific). Lysate quality control was verified by the presence of 
two well-separated peaks at 200-230 nm and 240-280 nm.  Cell lysates (80 μg of protein 
resuspended in 75 μL of labeling buffer) were incubated with biotin solution (10 μg/uL in N,N-
Dimethylformamide) for 2 h at ambient temperature, vortexing for 15 s every 10 min. Stop 
Reagent (35 μL) was then added biotinylated samples, which were then vortexed for 15 s, 
quickly spun and incubated at ambient temperature for 30 min, vortexing for 15 s every 5 min. 
Microarray slides were blocked with blocking solution (30 mL) for 45 min on an orbital shaker 
at 55 rpm at ambient temperature and then rinsed 10 times with ddH20 ddH20 in a 50 mL 
conical tube, shaking for 10 sec each time. Slides were then immersed in 6 mL of protein 
coupling solution mixed with biotinylated lysate and incubated for 2 h on an orbital shaker at 55 
rpm at ambient temperature. Slides were then transferred to Petri dish containing 30 mL of wash 
solution and washed 3 times for 10 min on an orbital shaker at 55 rpm at ambient temperature, 
then rinsed 10 times with ddH20 in a 50 mL conical tube, shaking for 10 s each time. Next, 
slides were incubated in solution containing 30 μL of Cy3-Streptavidin (0.5 mg/mL, GE 
Healthcare) in 30 mL of detection buffer in an aluminum foil covered petri dish for 20 min on 
an orbital shaker at 35 rpm. Slides were then transferred to Petri dish containing 30 mL of wash 
solution and washed twice for 10 min and then once overnight rotating on an orbital shaker at 
55 rpm at ambient temperature, then rinsed 10 times with ddH20 in a 50 mL conical tube, 
shaking for 10 s each time. Slides were dried by centrifugation, placing each slide in a 50 mL 
conical tube and centrifuging them at 1300 g for 10 min. Slides were scanned on a GenePix 
 94 
4000B Microarray Scanner (Molecular Devices) at 500 PMT and fluorescence quantification 
information was extracted using GenePix Pro 6.0 Software (Molecular Devices).  
4.2.2 Microarray Data Analysis 
Data mining was performed using the R environment version 3.0 [317]. Median fluorescence 
signal at wavelength 532 minus the local background at wavelength 532 (F532-B532) for each 
feature (i.e. area of interest in image analysis) was used for calculations. For comparison of total 
protein abundance and phosphorylation between control and Fabry disease podocytes, fold 
changes of normalized median fluorescence values for each corresponding feature were 
calculated by dividing the value obtained for GLA edited podocyte lysates to the value obtaining 
for control cells. When value was lesser than 1, the inverse number multiplied to -1 was used. 
Fold change values greater than or equal to 1.2 (upregulation) or lesser than or equal to -1.2 
(downregulation) were considered significant. Shapiro-Wilk test with α of 0.05 was used to test 
for normality. Values were represented as a log2 transformation.  
4.2.3 Microarray Analysis Quality Control  
A conservative approach was used throughout the quality control process to minimize false 
positive results. Only true values of fluorescence were used for further analysis. Measurements 
were considered true values when fluorescence signal for each spot was greater than 3 times the 
average of the median fluorescence signal of empty spots. When normalized fluorescence of 
replicates for a certain variable had values that overlapped between Fabry disease podocytes and 
control podocytes, a value of 1 was attributed to the fold change (i.e. no difference between 
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control and Fabry disease podocytes). As a noticeable proportion of variables showed 
coefficient of variation (CV) between replicates greater than 0.2, the fold changes were 
calculated by using values that showed minimal difference between Fabry disease and control 
podocytes. In total protein analysis, for proteins that were represented more than once (i.e. 
several total antibodies against the same protein), the most conservative number was used for 
analysis (i.e. the fold change value that was closest to 1). When fold change showed conflicting 
results among different epitopes representing the same protein (i.e. fold change results showing 
that same protein underwent both up and downregulation), these proteins were excluded from 
further analysis. Verification of expression of each individual protein in podocytes was 
performed using the Mouse Podocyte mRNA Database (available at 
http://helixweb.nih.gov/ESBL/Database/Podocyte_Transcriptome/index.htm) [318] and the 
NCBI Gene Expression Omnibus (GEO) Database [319, 320].  
4.2.4 Enrichment Analysis  
Site-specific information on protein regulation, upstream kinases and/or phosphatases and 
expected biological action were obtained using PhosphoSitePlus® (PSP) (Cell Signaling 
Technology®) [321]. Functional annotation, gene ontology functional classification, clustering 
and pathway analysis of significant data (fold change values greater than or equal to 1.2 or 
lesser than or equal to -1.2) were performed using Database for Annotation Visualization and 
Integrated Discovery (DAVID) Bioinformatics Resources 6.7 [National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health] [322], considering all proteins tested 
in the array as the background population.  
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4.3 RESULTS 
4.3.1 Phospho-Explorer Antibody Array of Fabry disease and control human 
immortalized podocytes 
I generated a cell model of Fabry disease in human immortalized podocytes using 
CRISPR/Cas9 targeting exons 1 and 7 of the GLA gene, which is described in Chapter 3. These 
cells show absence of α-gal A activity and present increased levels of globotriaosylceramide 
(Gb3), the main substrate of α-gal A, which is known to accumulate in Fabry disease. I carried 
out an A280 absorbance assay to verify the quality of the lysates preparation. Both samples 
presented well-separated peaks at 200-230 and 240-280 nm,.  
Using an exploratory approach to assess changes in abundance and phosphorylation of 
signaling molecules in Fabry disease nephropathy, I performed an antibody microarray in 
control and Fabry disease human immortalized podocytes. This array contains 1318 total and 
phosphorylation-specific antibodies antibodies against 414 different proteins and 686 
phosphorylation sites in duplicate, allowing for high-throughput parallel analysis of abundance 
and phosphorylation of those proteins of interest in control and Fabry disease podocytes (refer 
to Figure 16 for schematic).  
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Figure 16: Schematic of the microarray experiment. 
Cell lysates are incubated onto glass slides, which contain covalently bound total and phosphorylation-
specific antibodies against the proteins of interest. Proteins are then biotinylated, followed by incubation 
with Cy3-streptavidin. Cy3 fluorescence is measured using a microarray fluorescence scanner.  
 
I performed the microarray experiments in control and Fabry disease podocyte lysates, 
using biotin/Cy3-streptavidin for protein/primary antibody binding detection. Log2-transformed 
values of the median fluorescence intensity per pixel for each feature, applying a local 
background subtraction method, are represented in Figure 17. 
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Figure 17: Scattered plot of microarray results. 
Log2 transformed values of Cy3 median fluorescence intensity minus local background at wavelength 
532 for each feature in the microarray for control (X axis) and Fabry disease podocytes (Y axis).  
4.3.2 Total protein abundance analysis 
The total abundance of signaling proteins impacts the status and extent of protein interactions 
leading to signaling cascades or networks. Class comparison or differential expression of 
proteins provides quantitative information on the analogy of the abundance of given proteins 
between two sets of samples. In differential expression analysis, fold change values of 1 imply 
no difference between samples when using non-transformed values, and the negative inverted 
fold change is calculated when the value attributed to the experimental sample is lesser than that 
of the control sample.  
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I first compared the total abundance of these signaling proteins between Fabry disease 
and control podocytes by calculating the fold change for each individual epitope. As significant 
variability was seen among several of the replicates, I chose to apply conservative approaches 
instead of measures of central tendency (i.e. mean, median). I selected for fold change 
calculations the two closest values between Fabry disease and control podocytes. Fold change 
values for all represented epitopes are illustrated in Figure 18.  
 
Figure 18: Fold change in fluorescence intensity for total protein abundance in Fabry disease podocytes 
compared to control podocytes. 
 
Dashed lines correspond to the cutoffs of 1.2 and -1.2 fold changes.  
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I then selected candidate proteins based on a fold change threshold of greater than 1.2 or 
less than -1.2. For proteins covered multiple times through different epitopes, I eliminated those 
with conflicting results from further analysis. For those proteins that showed concordant values 
of fold change among epitopes, I again applied a conservative approach instead of a measure of 
central tendency for selecting the fold change value to be used, choosing the fold change values 
closest to 1.  
This analysis demonstrated that 21 phosphoproteins in the array show differences in 
total protein abundance. Nine phosphoproteins showed increased total protein abundance in 
Fabry disease podocytes (Table 3), while 12 proteins had decreased levels in Fabry disease 
podocytes compared to control podocytes (Table 4). 
 
Table 3: Phosphoproteins that showed increased total abundance in Fabry disease podocytes compared to 
control podocytes. 
 
Protein (official full name) Gene 
symbol  
Fold 
change 
Integrin, beta 1 (fibronectin receptor, beta polypeptide) ITGB1 2.04 
Paxillin PXN 1.50 
Gab2 (GRB2-associated binding protein 2) GAB2 1.42 
IR (Insulin receptor) INSR 1.33 
EGFR (Epidermal growth factor receptor) EGFR 1.28 
eIF4E (Eukaryotic translation initiation factor 4E) EIF4E 1.26 
Stathmin 1 STMN1 1.26 
IkB-beta (Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, beta) 
NFKBIB 1.20 
TGFBR1 (Transforming growth factor, beta receptor 1) TGFBR1 1.20 
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Table 4: Phosphoproteins that showed decreased total abundance in Fabry disease podocytes compared to 
control podocytes. 
 
Protein (official full name) Gene 
symbol  
Fold 
change 
p53 (Tumor protein p53) TP53 -1.42 
BTK (Bruton agammaglobulinemia tyrosine kinase) BTK -1.41 
Survivin (Baculoviral IAP repeat containing 5) BIRC5 -1.29 
HER2 (Erb-b2 receptor tyrosine kinase 2) ERBB2 -1.29 
NFkB-P65(V-rel avian reticuloendotheliosis viral oncogene 
homolog A) 
RELA -1.28 
PAK4 (p21 protein (Cdc42/Rac)-activated kinase 4) PAK4 -1.27 
FKHR/FOXO1A (Forkhead box O1) FOXO1 -1.26 
Smad2 (SMAD family member 2) SMAD2 -1.26 
FAK (Protein tyrosine kinase 2) PTK2 -1.26 
PDGFR beta (Platelet-derived growth factor receptor, beta 
polypeptide) 
PDGFRB -1.25 
MAP3K8/COT (Mitogen-activated protein kinase kinase kinase 8) MAP3K8 -1.25 
ASK1 (Mitogen-activated protein kinase kinase kinase 5) MAP3K5 -1.24 
 
4.3.3 Phosphorylation-specific analysis 
Phosphorylation is the main form by which protein function is regulated and intracellular 
signaling is transduced. The availability of antibodies that recognize phosphorylated peptides, 
allowing for specific recognition of proteins in its post-translational modified phosphorylated 
state, opens opportunities to study intracellular signaling in the context of health and disease. To 
estimate differences in phosphorylation in signaling proteins between Fabry disease and control 
podocytes, I used a similar approach to that of total abundance analysis. Fold change in signal 
intensity values for phosphorylation-specific antibodies between Fabry disease and control 
podocytes are seen in Figure 19. Again, a threshold of +/- 0.2 was set to assess significant 
differences in phosphorylation.  
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Figure 19: Fold change in fluorescence intensity of phosphorylation sites in phosphoproteins in Fabry 
disease podocytes compared to control podocytes. 
 
Dashed lines correspond to the cutoffs of 1.2 and -1.2 fold changes. 
 
A total of 43 proteins showed differences in phosphorylation in 51 specific sites. 
Increased phosphorylation was noted in13 phosphorylation sites of 12 different proteins (Table 
5) and decreased phosphorylation was observed in 38 sites of 33 different signaling proteins 
(Table 6). Some proteins showed both an increase and decrease in phosphorylation for different 
sites.  
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Table 5: Phosphorylation sites and respective phosphoproteins that showed increased fluorescence in Fabry 
disease podocytes compared to control podocytes. 
 
Protein (Official full name) Phosphorylation site Gene 
symbol 
Fold 
change 
P90RSK (Ribosomal protein S6 kinase, 90 kDa, 
polypeptide 1) 
Phospho-Thr359/Ser363 RPS6KA1 2.88 
HSP27 (Heat shock 27kDa protein 1) Phospho-Ser82 HSPB1 2.64 
CBL (Cbl proto-oncogene, E3 ubiquitin protein 
ligase) 
Phospho-Tyr700 CBL  2.45 
IKK-beta (Inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase beta) 
Phospho-Tyr188 IKBKB 1.82 
Synuclein, alpha  Phospho-Tyr133 SNCA 1.50 
PKC delta (Protein kinase C, delta) Phospho-Ser645 PRKCD 1.41 
p38 MAPK (Mitogen-activated protein kinase 
14) 
Phospho-Tyr182 MAPK14 1.40 
CD3Z (CD247 molecule) Phospho-Tyr142 CD247 1.37 
NFkB-p65 (V-rel avian reticuloendotheliosis 
viral oncogene homolog A) 
Phospho-Ser536 RELA 1.35 
SMAD family member 3 Phospho-Ser204 SMAD3 1.35 
PDGFR beta (Platelet-derived growth factor 
receptor, beta polypeptide) 
Phospho-Tyr751 PDGFRB 1.34 
STAT5A (Signal transducer and activator of 
transcription 5A) 
Phospho-Ser725 STAT5A 1.34 
IKK-beta (Inhibitor of kappa light polypeptide 
gene enhancer in B-cells, kinase beta) 
Phospho-Tyr199 IKBKB 1.30 
 
 
Table 6: Phosphorylation sites and respective phosphoproteins that showed decreased fluorescence in Fabry 
disease podocytes compared to control podocytes. 
 
Protein (official full name) Phosphorylation site Gene 
symbol 
Fold change 
HER2 (Erb-b2 receptor tyrosine kinase 2)  Phospho-Tyr877 ERBB2 -2.71 
MEK1 (Mitogen-activated protein kinase kinase 
1) 
Phospho-Ser217 MAP2K1 -2.54 
TYK2 (Tyrosine kinase 2) Phospho-Tyr1054 TYK2 -1.87 
Rb (Retinoblastoma 1) Phospho-Ser807 RB1 -1.54 
CD45 (Protein tyrosine phosphatase, receptor 
type, C) 
Phospho-Ser1007 PTPRC -1.53 
Mst1/Mst2 (Serine/threonine kinase 4) (Phospho-Thr183 STK4/STK3 -1.53 
Synaptotagmin I Phospho-Thr202 SYT1 -1.52 
HDAC1 (Histone deacetylase 1) Phospho-Ser421 HDAC1 -1.49 
Rb (Retinoblastoma 1) Phospho-Thr821 RB1 -1.49 
ATP citrate lyase Phospho-Ser454 ACLY -1.48 
Tau (Microtubule-associated protein tau) Phospho-Thr212 MAPT -1.48 
JAK1 (Janus kinase 1) Phospho-Tyr1022 JAK1 -1.47 
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KCNIP3 (Kv channel interacting protein 3, 
calsenilin) 
Phospho-Ser63 KCNIP3 -1.43 
HDAC2 (Histone deacetylase 2) Phospho-Ser394 HDAC2 -1.38 
BAD (BCL2-associated agonist of cell death) Phospho-Ser134 BAD -1.37 
PKC beta (Protein kinase C, beta) Phospho-Ser661 PRKCB -1.34 
p44/42 MAPK (Mitogen-activated protein kinase 
3) 
Phospho-Thr202 MAPK3 -1.33 
Ephrin-B1/B2/B3 Phospho-Tyr324 EFNB1/2/3 -1.32 
STAT3 (Signal transducer and activator of 
transcription 3 (acute-phase response factor)) 
Phospho-Ser727 STAT3 -1.3 
p53 (Tumor protein p53) Phospho-Ser315 TP53 -1.29 
Smad3 (SMAD family member 3) Phospho-Ser425 SMAD3 -1.29 
c-Ab (ABL proto-oncogene 1, non-receptor 
tyrosine kinase) 
Phospho-Tyr412 ABL1 -1.28 
EPHA2/3/4 (EPH receptor A2/3/4) Phospho-Tyr588/596 EPHA2 -1.28 
AKT1 (V-akt murine thymoma viral oncogene 
homolog 1) 
Phospho-Thr308 AKT1 -1.26 
STAT5B (Signal transducer and activator of 
transcription 5B) 
Phospho-Ser731 STAT5B -1.26 
FAK (Protein tyrosine kinase 2) Phospho-Tyr407 PTK2 -1.25 
IL-10R-alpha (Interleukin 10 receptor, alpha) Phospho-Tyr496 IL10RA -1.24 
Rb (Retinoblastoma 1) Phospho-Ser811 RB1 -1.24 
CDK2 (Cyclin-dependent kinase 2) Phospho-Thr160 CDK2 -1.23 
DAB1 (Dab, reelin signal transducer, homolog 1) Phospho-Tyr232 DAB1 -1.23 
Protein tyrosine kinase 2 Phospho-Tyr861 PTK2 -1.23 
Tyrosine hydroxylase Phospho-Ser31 TH -1.23 
WEE1 G2 checkpoint kinase Phospho-Ser642 WEE1 -1.23 
Cyclin B1 Phospho-Ser126 CCNB1 -1.22 
PAK2 (p21 protein (Cdc42/Rac)-activated kinase 
2) 
Phospho-Ser192 PAK2 -1.22 
Tau (Microtubule-associated protein tau) Phospho-Ser356 MAPT -1.22 
Synaptotagmin I Phospho-Ser309 SYT1 -1.21 
HER2 (Erb-b2 receptor tyrosine kinase 2) Phospho-Thr686 ERBB2 -1.2 
Protein (official full name) Phosphorylation site 
Gen
e symbol 
Fol
d change 
HER2 (Erb-b2 receptor 
tyrosine kinase 2) 
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BB2 
-
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protein kinase kinase 1) 
Phospho-
Ser217 
MA
P2K1 
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K2 
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Synaptotagmin I Phospho-Thr202 
SY
T1 
-
1.52 
HDAC1 (Histone 
deacetylase 1) 
Phospho-
Ser421 
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transducer, homolog 1) Tyr232 B1 1.23 
Protein tyrosine kinase 2 Phospho-Tyr861 
PT
K2 
-
1.23 
Tyrosine hydroxylase Phospho-Ser31 TH 
-
1.23 
WEE1 G2 checkpoint 
kinase 
Phospho-
Ser642 
WE
E1 
-
1.23 
Cyclin B1 Phospho-Ser126 
CC
NB1 
-
1.22 
PAK2 (p21 protein 
(Cdc42/Rac)-activated kinase 2) 
Phospho-
Ser192 
PA
K2 
-
1.22 
Tau (Microtubule-
associated protein tau) 
Phospho-
Ser356 
MA
PT 
-
1.22 
Synaptotagmin I Phospho-Ser309 
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T1 
-
1.21 
HER2 (Erb-b2 receptor 
tyrosine kinase 2) 
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Thr686 
ER
BB2 -1.2 
 
 
4.3.4 Gene Set Enrichment Analysis 
I next performed a gene ontology enrichment analysis of positive array findings, which 
comprised proteins with at least 20 percent difference in either abundance or phosphorylation 
among Fabry disease and control podocytes. The gene ontology (GO) consortium is a 
collaborative effort to add uniformity and consistency to gene annotation. Functional 
descriptions and intracellular location of gene products and cellular processes that are 
implicated are described using a predefined vocabulary [323]. Table 7shows the top 5 hits in 
enrichment analysis based on GO terms for Fabry disease podocytes compared to control 
podocytes. These genes show only modest fold enrichment to the background gene population 
on the array. 
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Table 7: Gene set enrichment analysis. 
GO identifier Term Fold 
Enrichment 
Bonferroni Benjamini FDR 
GO:0051173 positive regulation of 
nitrogen compound 
metabolic process 
1.88 0.99 0.99 5.39 
GO:0045597 positive regulation of cell 
differentiation 
2.28 1.00 1.00 11.02 
GO:0051726 regulation of cell cycle 1.92 1.00 0.98 11.69 
GO:0040008 regulation of growth 2.22 1.00 0.97 13.72 
GO:004593 positive regulation of 
nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolic process 
1.82 1.00 0.95 14.97 
 
Clustering analysis of the candidate proteins at DAVID, including all 59 proteins that 
showed differences in either total abundance or phosphorylation and taking into account all 
proteins in the array as the background gene population, revealed a total of 73 enrichment 
clusters. To note, none of these clusters reached an enrichment score of 1.3 or higher, which is 
equivalent to a non-log scale of 0.05. A representation of the cluster that achieved the highest 
enrichment can be found on Figure 20.  
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Figure 20: Clustering annotation. 
Green squares represent fields where a corresponding protein-GO term association has been previously 
reported. 
4.3.5 Expression of candidate proteins in podocytes 
Repositories of gene expression data facilitate the storage and sharing of transcriptome 
information. Many peer-reviewed journals as well as funding sources currently require principal 
investigators to make their raw gene expression data publicly available, allowing for 
independent researchers to combine information from several previous studies and to generate 
and test novel hypotheses. The National Center for Biotechnology (NCBI) gene expression 
omnibus (GEO) is the largest gene expression resource publicly available [319, 320]. 
Hence, I searched publicly available transcriptome databases for expression information 
of candidate proteins in podocytes. Surprisingly, four of the 21 proteins that showed differences 
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in total abundance as well as 13 of the 51 proteins with differential phosphorylation pattern 
could not be located in the RNA sequencing expression database of mouse podocytes performed 
by Kann et al. [318] and available on the Renal Epithelial Transcriptome and Proteome 
Databases website (http://helixweb.nih.gov/ESBL/Database). Moreover, none of those proteins 
could be identified in the transcriptomic (Affymetrix Mouse Gene 1.0 ST microarray) and 
proteomic (SILAC) data on freshly isolated mouse podocytes recently published by Boerries et 
al. [314]  A comprehensive list of these proteins can be found in Table 8. 
Interestingly, inquiry for these same dataset of candidate proteins on the GEO 
repository, limiting the search to studies performed in podocytes, revealed that all candidate 
proteins were identified as expressed in the transcriptome of the conditionally immortalized 
human podocyte cell line generated by Saleem et al. [324] according to expression profiling 
performed by Da Sacco et al [325] using the Affymetrix Human Gene 1.0 ST microarray (NCBI 
GEO database accession GSE49439).  
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Table 8: Candidate proteins not found to be expressed in mouse podocytes. 
Name Gene symbol Microarray category 
Cyclin B1 CCNB1 Total protein 
CD3Z/CD247 molecule CD247 Total protein 
Baculoviral IAP repeat containing 5 BIRC5 Total protein  
Tumor protein p53 TP53 Total protein and 
phosphorylated form 
Cyclin B1 CCNB1 Phosphorylated form 
CD247 molecule CD247 Phosphorylated form 
Dab, reelin signal transducer, homolog 1 (Drosophila) DAB1 Phosphorylated form 
Interleukin 10 receptor, alpha IL10RA Phosphorylated form 
Kv channel interacting protein 3, calsenilin KCNIP3 Phosphorylated form 
Protein kinase C, beta PRKCB Phosphorylated form 
Protein tyrosine phosphatase, receptor type, C PTPRC Phosphorylated form 
Ribosomal protein S6 kinase, 90 kDa, polypeptide 1 RPS6KA1 Phosphorylated form 
Synuclein, alpha  SNCA Phosphorylated form 
Signal transducer and activator of transcription 5A STAT5A Phosphorylated form 
Synaptotagmin I SYT1 Phosphorylated form 
Tyrosine hydroxylase TH Phosphorylated form 
From Kann et al. [318] 
 
4.3.6 Pathway enrichment analysis 
Pathway analysis of all the phosphoproteins represented in the array was carried out using the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) function of the Database for Annotation 
Visualization and Integrated Discovery (DAVID) Bioinformatics Resources. This analysis 
reveals enrichment for 65 different signaling pathways, covering a variety of intracellular 
processes crucial for cell function. [326, 327] 
KEGG pathway analysis of candidate proteins reveals 11 pathways being over-
represented among those with significant fold changes between Fabry disease and control 
podocytes (Table 9). An illustration of proteins differentially expressed in the context of the 
MAPK pathway is seen in Figure 21.  
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Table 9: KEGG canonical pathways most represented in number of genes among the candidate proteins. 
KEGG 
Pathway ID 
Description Count P value Fold 
Enrichment 
Bonferroni Benjamini FDR 
hsa05200 Pathways in cancer 29 0.00013 1.80 0.0098 0.0098 0.13 
hsa05220 Chronic myeloid 
leukemia 
17 0.00024 2.41 0.0185 0.0093 0.25 
hsa05212 Pancreatic cancer 15 0.00073 2.41 0.0550 0.0187 0.76 
hsa05223 Non-small cell lung 
cancer 
10 0.01998 2.20 0.7929 0.3254 19.23 
hsa04010 MAPK signaling 
pathway 
19 0.04409 1.49 0.9703 0.5051 37.93 
hsa05210 Colorectal cancer 11 0.05134 1.82 0.9836 0.4960 42.73 
hsa04660 T cell receptor 
signaling pathway 
13 0.06122 1.64 0.9928 0.5053 48.74 
hsa05215 Prostate cancer 13 0.06122 1.64 0.9928 0.5053 48.74 
hsa05221 Acute myeloid 
leukemia 
9 0.06919 1.91 0.9963 0.5030 53.16 
hsa04370 VEGF signaling 
pathway 
9 0.06919 1.91 0.9963 0.5030 53.16 
hsa04012 ErbB signaling 
pathway 
14 0.07944 1.54 0.9984 0.5120 58.34 
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Figure 21: Candidate proteins in the context of the MAPK signaling pathway. 
Proteins in red showed decreased and protein in blue showed increased abundance and/or 
phosphorylation in Fabry disease and control podocytes.   
 
4.4 DISCUSSION 
Assessing changes in homeostasis of signaling proteins, from differences in expression to 
changes in activation, self and hetero-association, stabilization or degradation are crucial to a 
better understanding of the intracellular mechanisms in health and disease. Using a high 
throughput approach that takes into account post-phosphorylation, I obtained parallel 
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information on the abundance and phosphorylation of hundreds of signaling proteins in Fabry 
disease podocytes. The 59 phosphoproteins that showed at least a 20 percent difference in either 
total abundance or phosphorylation between Fabry disease and control podocytes (i.e. positive 
array findings) are considered “candidate proteins” to validate further. Gene ontology and 
clustering analysis of these proteins showed a slight enrichment for proteins involved in cell 
growth and differentiation and cell death in Fabry disease podocytes, which correlates well with 
the fact that I observe differences in proliferation and/or cell death in these Fabry disease 
podocytes when compared to control podocytes.  
The antibody microarray used in this study is enriched for 65 different signaling 
pathways that are relevant to human disease, several of which have been implicated in the 
pathogenesis of other glomerular diseases. Pathway analysis revealed that MAPK and VEGF 
pathways as well as nine other different signaling pathways as being significantly enriched or 
overrepresented among our candidate proteins. The MAPK pathway seems to play a critical role 
in kidney development [328-330]. Through its interplay with the NFkB pathway, MAPK 
pathway is also implicated in the pathophysiology of steroid responsive glomerulopathies. [331] 
Other physiologically relevant signaling pathways that did not show statistically 
significant enrichment when compared to the background proteins tested in the array but that 
are considerably represented among the candidate proteins are also worth exploring further. For 
instance, the PI3K/Akt/mTOR pathway had a substantial number of candidate proteins 
represented (14 proteins, data not shown). The PI3K pathway is also crucial in kidney 
development [332]. Accordingly, podocyte injury with proteinuria is a relatively common 
“second-hit” complication of the use of sirolimus (rapamycin) and everolimus, clinically used 
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mTOR inhibitors, in patients with underlying kidney disease and/or previous history of use of 
immunosuppressant drugs. [333, 334] 
Previous work by Lee et al. [335] in Fabry disease mice suggested that VEGF and TGF-
beta signaling might contribute to Fabry disease nephropathy. VEGF pathway showed 
statistically significant enrichment, and several components of the TGF-beta pathway also 
showed differences in protein abundance and phosphorylation. Perturbed TGF-beta signaling 
has also been implicated in the pathogenesis of renal fibrosis leading to focal segmental and 
global glomerulosclerosis seen in several chronic glomerular diseases, including Fabry disease. 
[336, 337] Deregulated TGF-beta signaling is also thought to be a major contributor to podocyte 
epithelial mesenchymal transition (EMT). [338] 
Quantitative proteomics remains the method of choice for protein discovery in complex 
biological samples. [339] Nonetheless, targeted strategies using antibody microarrays achieve 
semi-quantitative information on a large number of proteins of interest with known regulatory 
mechanisms, which facilitate validation and interpretation of the results.  
Microarray analysis involves four main steps: (i) sample preparation and microarray 
experiment, (ii) image analysis and fluorescence signal acquisition, (iii) data normalization and 
quality control, and (iv) higher level analysis and functional interpretation of results. The first 
two steps are subject to sources of unwanted signal variation that may interfere with 
interpretation of the results. In addition, proper normalization procedures and application of 
quality control measurements helps account for technical variations. Normalization methods 
vary broadly and should be tailored to each specific set of experiments. Choosing the most 
conservative approaches for normalization and quality control allows for elimination of artifacts 
or false positive results, which is preferable since it reduces uncertainties.  
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Our study presents some limitations to consider. Human immortalized podocytes 
maintained in culture fail to present some of the morphological and functional features seen in a 
podocyte in vivo, such as interdigitating foot processes, as well as expression of slit diaphragm 
podocyte-specific proteins such as nephrin, which are crucial for podocyte function. Even 
though all proper controls were applied, as both control and Fabry disease cells used in the 
study have undergone lipofectamine treatment as well as the same number of passages, some of 
the changes in signaling that are observed in vitro may not be relevant for human disease in 
vivo. Unfortunately, none of the podocyte-specific proteins was covered in our microarray. To 
the best of our knowledge, none of the commercially available antibody microarrays allows for 
analysis of those podocyte-specific proteins. Another key point is that none of the components 
of the Coordinated Lysosomal Expression and Regulation (CLEAR) gene network was 
represented in this study. Certainly some of these proteins would be expected to have different 
activation pattern in Fabry disease podocytes, which could not be detected using our approach.  
A database search in previously published transcriptome literature demonstrated that 
some of our candidate proteins were only found to be expressed in human cultured podocytes 
and not present in FACS sorted mouse podocytes. Several factors can explain these differences: 
(i) podocytes are post-mitotic highly differentiated cells. When exposed to an artificial 
environment in culture, where they proliferate at a much greater rate, it is not uncommon for 
podocytes to undergo substantial changes in morphology and expression of podocyte-specific 
markers [340], thus, it would not surprising if the expression profile of signaling proteins is 
altered in vitro compared to in vivo. (ii) These differences can arise from species-specific 
differences in expression of signaling proteins between mouse and human podocytes. Renal 
pathophysiology of mice is considerably different from that of humans. Healthy mice present 
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some proteinuria as baseline, which is not seen in humans [341] and their kidneys are quite 
resistant to Gb3 buildup. As previously mentioned, neither the Gla KO mice alone nor when 
interbred with mice expressing transgenic Gb3 synthase to significantly increase Gb3 
accumulation present renal dysfunction to the extent of what is seen in humans [104]. (iii) The 
experiments were performed by different groups, using different methodologies (i.e. RNA-seq 
vs. DNA microarrays), which could result in differences in transcript detection.  The yield of 
human podocytes from biopsy specimens is very low, hampering cell-type specific in vivo 
studies of gene expression. However, as the next generation sequencing technologies advance to 
single cell “omics” studies [342], this type of analysis might be feasible in the future.  
Another factor to consider is that some of the differences in signaling that were revealed 
through the microarray analysis could potentially have actually derived from the CRISPR/Cas9 
treatment itself. For instance, double-stranded DNA breaks induced by Cas9 trigger the 
activation of the DNA repair machinery, especially of those proteins involved in non-
homologous end-joining (NHEJ) pathway, which includes DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs), Artemis, Polymerases λ and μ, XRCC4 and ligase IV. [343] 
Some of these DNA repair proteins are also involved in other signaling pathways, notably those 
related to cell cycle. [344] Nevertheless, changes in signaling that are due to DNA repair 
activation would be unlikely to be seen in the cell population lysed for the microarray 
experiment, as they expanded from approximately 100,000 cells when they undergone 
CRISPR/Cas9 treatment to 5 million cells before the microarray was performed.   
The accuracy and sensitivity of the antibody microarray analysis rely upon affinity and 
specificity of the probed antibodies, and antibodies are inherently prone to unpredicted, sample-
specific interferences, yielding false positive or negative results [345]. Some probed antibodies 
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are also known to lack of specificity, since they cannot distinguish between some proteins that 
are highly similar in structure (i.e. Ephrin B1/B2/B3, EPHA 2/3/4). As those proteins do not 
completely overlap in their function and regulation, other approaches should be used in these 
instances to differentiate the individual contribution of a specific protein. Another factor to 
consider is when performing class comparison with proteins that show low signal intensity in 
the microarray, either due to low abundance of that protein in the biological sample or due to 
low antibody affinity. An inherent bias on those cases is that fold change values will have a 
much larger variance when comparing with proteins that show higher signal intensity. [346] 
Another limitation of this microarray is that due to a limited number of spots or features that can 
be probed in a single slide, a large number of variables are tested with a limited number of 
technical replicates. In the specific case of our microarray, each epitope was probed only twice. 
A considerable number of these technical replicates presented a higher than optimal coefficient 
of variation (CV). In addition, several proteins were covered multiple times through different 
epitopes, while others were represented only through a single epitope, thus our analysis was also 
biased through a differential power to detect any differences in abundance of individual 
proteins.  
Proper functional interpretation of phosphoproteomics or phospho-antibody microarray 
results can be very challenging. While bioinformatics tools are evolving at exponential rates, the 
vast majority of used in enrichment analysis do not account for post-translational modifications 
and their effect on protein function as well as any differential regulatory effects exerted by each 
individual component of a given pathway or gene network. In addition, as our understanding of 
protein function and protein interactions also expands, new connections or relationships among 
well-established canonical pathways are discovered, and boundaries of individual pathways 
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start blurring [347]. Furthermore, fold change representation of proteins takes the assumption 
that the effect of the abundance of a given protein is multiplicative and independent from one 
another; however, in general, the biological effects of changes in protein abundance are largely 
unknown, and could well be additive or exponential and also dependent on the changes seen in 
other interacting proteins within a cascade or network.  
4.5 CONCLUSION 
In brief, antibody microarrays can be an excellent exploratory resource to generate and test 
hypothesis about disease pathogenesis. I performed a phosphoantibody microarray to assess 
differences in abundance and phosphorylation of signaling proteins in Fabry disease podocytes. 
Our analysis unfolded several candidate proteins and canonical pathways that could potentially 
be implicated in the pathophysiology of Fabry nephropathy.  
 
4.6 FUTURE DIRECTIONS 
Candidate proteins should be validated using established immunoassays such as Western 
blotting or indirect immunofluorescence, preferably in several control and Fabry disease 
CRISPR/Cas9-treated podocyte populations. Rescue experiments using heterologous expression 
of α-gal A and/or recombinant enzyme would ensure that the changes observed in protein 
abundance or phosphorylation are not a result of off-target effects of the genome editing 
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technique and are responsive to recombinant enzyme treatment. In tissue validation using Fabry 
disease and wild-type mice glomeruli would provide stronger evidence of these findings. Yet, 
negative validation results in mice should be interpreted with caution. While Fabry disease mice 
show biochemical features of the disease, they do not present classic signs of Fabry 
nephropathy. [101] Ideally, histopathology analysis of these proteins in kidney biopsy samples 
of Fabry disease patients in various stages of the disease and matched controls would provide 
some temporal information on the cascade of intracellular events leading to renal failure in these 
patients. 
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APPENDIX A: ABBREVIATONS 
α-gal A  Alpha-galactosidase A 
CLEAR Coordinated Lysosomal Expression and Regulation 
CKD  Chronic Kidney Disease  
CRISPR/Cas9 Clustered Regularly Interspaced Short Palindromic Repeats and associated 
nuclease 9 
CV  Coefficient of variation 
DPPIV  Dipeptidylpeptidase IV 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DSB  Double-strand break 
EEA1   Early endosomal antigen 1  
EMT  Epithelial-mesenchymal transition 
ERT  Enzyme replacement therapy 
FACS  Fluorescence-activated cell sorting 
Gb3  Globotriaosylceramide 
GEO  Gene Expression Omnibus 
GO  Gene ontology 
GPI  Glycosylphosphatidylinositol  
HA  Hemagglutinin 
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KEGG  Kyoto Encyclopedia of Genes and Genomes 
LAMP-2 Lysosomal membrane associated protein 2 
LSD  Lysosomal storage disorder 
MDCK Madin-Darby canine kidney 
N&B  Number and brightness 
NHEJ  Non-homologous end joining 
RT-PCR Reverse transcription polymerase chain reaction 
qRT-PCR Real-time quantitative reverse-transcription polymerase chain reaction 
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APPENDIX B: SUPPLMENTARY FIGURES 
 
 
Supplementary Figure 1: Morphology and distribution of early endosomes and the Golgi complex are 
unaffected by α-gal A siRNA silencing.  
 
Indirect immunofluorescence staining for the early endosome marker EEA1 and the Golgi complex 
marker giantin in MDCK cells transfected with control or α-gal A siRNA. Scale bar: 10 µm. 
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Supplementary Figure 2: Steady-state distribution of raft-associated and raft-independent basolateral 
cargoes is not perturbed by α-gal A siRNA silencing. 
 
Indirect immunofluorescence staining of the raft-independent cell adhesion protein E-cadherin (upper 
panels), the raft associated pump Na+/K+ ATPase (middle panels) and the raft associated scaffolding 
protein caveolin-1 (lower panels) in cells transfected with control siRNA (left) and α-gal A siRNA 
(right) for four days. Images taken at the level of the apical surface and at a medial plane are shown for each 
protein, and xz reconstructions are shown below. Scale bar: 5 µm 
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Supplementary Figure 3: Representative brightness vs. intensity histograms of GFP-GPI in untreated and 
antibody-clustered control and α-gal A silenced cells.  
 
Histograms (Brightness vs. Intensity) for control and α-gal A siRNA treated MDCK cells expressing 
GFP-GPI in the absence (-Ab) or presence (+Ab) of anti-GFP antibody. Individual points represent data 
from a single pixel within the region of interest (roi) shown adjacent to each plot. The y-axis values 
correspond to increasing brightness (i.e., a higher average oligomeric size of fluorescent particles in the 
pixel) while increasing x-axis values correspond to higher signal intensities within each pixel (i.e., higher 
levels of fluorescence intensity in that pixel). For example, a pixel containing large numbers of 
monomers would map to the intersection of a small y-axis value and large x-axis value. Conversely, a 
pixel containing a small number of larger oligomers would map to a larger y-axis value and a low value 
on the x-axis. Brightness values in these histograms are raw values of the sum of the molecular 
brightness and the detector noise and, in this plot, are not normalized to GFP. Subtraction of one from 
the B value gives ε (counts/dwell time/molecule). Multiplication of ε by the dwell time used for 
acquisition and divided by the average molecular brightness for GFP provides the normalized brightness 
as reported in Figure 5, which enables direct quantitation of oligomeric size (e.g., monomer, dimer, etc.). 
In the representative examples shown here, pixels bounded by the red rectangular box are mapped onto 
the adjacent roi image. Note that selected pixels map evenly across the entire imaged area of the cell 
(i.e., there are no brightness “hot-spots”). In contrast, numerous brighter pixels are evident in histograms 
of cells incubated with anti-GFP antibody, and these brighter pixels map to large clusters in the roi. 
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